WO2024073056A1 - Cucurbituril compositions, products, and methods of use - Google Patents
Cucurbituril compositions, products, and methods of use Download PDFInfo
- Publication number
- WO2024073056A1 WO2024073056A1 PCT/US2023/034135 US2023034135W WO2024073056A1 WO 2024073056 A1 WO2024073056 A1 WO 2024073056A1 US 2023034135 W US2023034135 W US 2023034135W WO 2024073056 A1 WO2024073056 A1 WO 2024073056A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cucurbituril
- intestinal microbial
- patient
- metabolite
- microbial metabolite
- Prior art date
Links
- MSBXTPRURXJCPF-DQWIULQBSA-N cucurbit[6]uril Chemical compound N1([C@@H]2[C@@H]3N(C1=O)CN1[C@@H]4[C@@H]5N(C1=O)CN1[C@@H]6[C@@H]7N(C1=O)CN1[C@@H]8[C@@H]9N(C1=O)CN([C@H]1N(C%10=O)CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@@H]6[C@H]4N2C(=O)N6CN%10[C@H]1N3C5 MSBXTPRURXJCPF-DQWIULQBSA-N 0.000 title claims abstract description 233
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims description 24
- 239000002207 metabolite Substances 0.000 claims abstract description 160
- 230000000968 intestinal effect Effects 0.000 claims abstract description 137
- 230000000813 microbial effect Effects 0.000 claims abstract description 129
- 210000002966 serum Anatomy 0.000 claims abstract description 40
- 239000002131 composite material Substances 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 238000000502 dialysis Methods 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 54
- 210000004369 blood Anatomy 0.000 claims description 50
- 239000008280 blood Substances 0.000 claims description 50
- 239000012528 membrane Substances 0.000 claims description 41
- -1 polytetrafluoroethylene Polymers 0.000 claims description 27
- 239000007787 solid Substances 0.000 claims description 21
- VPVSTMAPERLKKM-UHFFFAOYSA-N glycoluril Chemical compound N1C(=O)NC2NC(=O)NC21 VPVSTMAPERLKKM-UHFFFAOYSA-N 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000003440 toxic substance Substances 0.000 claims description 16
- 239000000178 monomer Substances 0.000 claims description 15
- 231100000167 toxic agent Toxicity 0.000 claims description 14
- 229920002284 Cellulose triacetate Polymers 0.000 claims description 12
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 230000000155 isotopic effect Effects 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 8
- 239000002033 PVDF binder Substances 0.000 claims description 8
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 8
- 239000004697 Polyetherimide Substances 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 229920000954 Polyglycolide Polymers 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 8
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 8
- 229920002492 poly(sulfone) Polymers 0.000 claims description 8
- 239000004417 polycarbonate Substances 0.000 claims description 8
- 229920000515 polycarbonate Polymers 0.000 claims description 8
- 229920001601 polyetherimide Polymers 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 239000004633 polyglycolic acid Substances 0.000 claims description 8
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 8
- 229920006324 polyoxymethylene Polymers 0.000 claims description 8
- 229920001155 polypropylene Polymers 0.000 claims description 8
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 8
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 8
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
- 239000003463 adsorbent Substances 0.000 claims description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 208000020016 psychiatric disease Diseases 0.000 claims description 6
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 229920000491 Polyphenylsulfone Polymers 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- JYAXYNMOHKXUNL-UHFFFAOYSA-N [Na].C=CC#N Chemical compound [Na].C=CC#N JYAXYNMOHKXUNL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000956 alloy Substances 0.000 claims description 4
- 229910045601 alloy Inorganic materials 0.000 claims description 4
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 4
- 239000004715 ethylene vinyl alcohol Substances 0.000 claims description 4
- DUGDVPXCHOVCOS-UHFFFAOYSA-N methyl prop-2-ene-1-sulfonate Chemical class COS(=O)(=O)CC=C DUGDVPXCHOVCOS-UHFFFAOYSA-N 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920002530 polyetherether ketone Polymers 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 239000004800 polyvinyl chloride Substances 0.000 claims description 4
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 claims description 3
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical compound COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 239000012510 hollow fiber Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000004753 textile Substances 0.000 claims description 2
- 229940070721 polyacrylate Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
- 201000010099 disease Diseases 0.000 abstract description 13
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical class C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 24
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 102000009027 Albumins Human genes 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 11
- DWZGLEPNCRFCEP-UHFFFAOYSA-N 4-ethylphenol sulfate Natural products CCC1=CC=C(OS(O)(=O)=O)C=C1 DWZGLEPNCRFCEP-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 150000004666 short chain fatty acids Chemical class 0.000 description 10
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 10
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 150000002678 macrocyclic compounds Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical class CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Chemical class C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000560 biocompatible material Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 208000002551 irritable bowel syndrome Diseases 0.000 description 6
- 235000021391 short chain fatty acids Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 235000021073 macronutrients Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000003050 macronutrient Effects 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- 229940074386 skatole Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 208000029560 autism spectrum disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- ZDOBFUIMGBWEAB-XGFHMVPTSA-N cucurbit[7]uril Chemical compound N1([C@H]2[C@H]3N(C1=O)CN1[C@H]4[C@H]5N(C1=O)CN1[C@H]6[C@H]7N(C1=O)CN1[C@H]8[C@H]9N(C1=O)CN1[C@H]%10[C@H]%11N(C1=O)CN([C@@H]1N(C%12=O)CN%11C(=O)N%10CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@H]6[C@@H]4N2C(=O)N6CN%12[C@@H]1N3C5 ZDOBFUIMGBWEAB-XGFHMVPTSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical class CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000002615 hemofiltration Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- HOMDJHGZAAKUQV-UHFFFAOYSA-N 1-(propoxymethoxy)propane Chemical compound CCCOCOCCC HOMDJHGZAAKUQV-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- RLYOPPJABLAKCZ-UHFFFAOYSA-N 2-butoxycarbonylbenzenecarboperoxoic acid Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OO RLYOPPJABLAKCZ-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 description 1
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100035041 Dimethylaniline monooxygenase [N-oxide-forming] 3 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- KHNXRSIBRKBJDI-UHFFFAOYSA-N Sevelamer hydrochloride Chemical compound Cl.NCC=C.ClCC1CO1 KHNXRSIBRKBJDI-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000011829 Trace amine associated receptor Human genes 0.000 description 1
- 108050002178 Trace amine associated receptor Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- CONWISUOKHSUDR-LBCLZKRDSA-N cucurbit[8]uril Chemical compound N1([C@@H]2[C@@H]3N(C1=O)CN1[C@@H]4[C@@H]5N(C1=O)CN1[C@@H]6[C@@H]7N(C1=O)CN1[C@@H]8[C@@H]9N(C1=O)CN1[C@@H]%10[C@@H]%11N(C1=O)CN1[C@@H]%12[C@@H]%13N(C1=O)CN([C@H]1N(C%14=O)CN%13C(=O)N%12CN%11C(=O)N%10CN9C(=O)N8CN7C(=O)N6CN5C(=O)N4CN3C(=O)N2C2)C3=O)CN4C(=O)N5[C@@H]6[C@H]4N2C(=O)N6CN%14[C@H]1N3C5 CONWISUOKHSUDR-LBCLZKRDSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011549 displacement method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000001046 glycoluril group Chemical class [H]C12N(*)C(=O)N(*)C1([H])N(*)C(=O)N2* 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- AFCUGQOTNCVYSW-UHFFFAOYSA-H lanthanum(3+);tricarbonate;hydrate Chemical compound O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O AFCUGQOTNCVYSW-UHFFFAOYSA-H 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- ZMHLUFWWWPBTIU-UHFFFAOYSA-N p-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=C(O)C=C1 ZMHLUFWWWPBTIU-UHFFFAOYSA-N 0.000 description 1
- JPAUCQAJHLSMQW-XPORZQOISA-N p-tolyl beta-D-glucuronide Chemical compound C1=CC(C)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 JPAUCQAJHLSMQW-XPORZQOISA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960003027 sevelamer hydrochloride Drugs 0.000 description 1
- 229940006186 sodium polystyrene sulfonate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- SZHIIIPPJJXYRY-UHFFFAOYSA-M sodium;2-methylprop-2-ene-1-sulfonate Chemical compound [Na+].CC(=C)CS([O-])(=O)=O SZHIIIPPJJXYRY-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/68—Biocompatibility of parts of the module
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/58—Other polymers having nitrogen in the main chain, with or without oxygen or carbon only
- B01D71/62—Polycondensates having nitrogen-containing heterocyclic rings in the main chain
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/76—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
Definitions
- Human intestinal microbiota include microorganisms such as bacteria that inhabit and maintain homeostasis of the gastrointestinal tract. These microorganisms contribute to the symbiotic ecosystem of the gastrointestinal tract.
- One benefit of the symbiosis is the metabolic activity of the microorganisms on exogenous and endogenous substrates, forming nutrients that arc useable by the human host.
- the presence of diverse metabolic activity in the human gastrointestinal tract allows the intestinal microbiota to fill available ecological niches and competitively inhibit colonization by pathogens.
- the gastrointestinal tract may have elevated concentrations of mostly acidic fermentation byproducts compared to other areas of the human body. These elevated concentrations of byproducts may reduce pH locally to create an inhospitable environment for pathogens.
- the gastrointestinal tract metabolites and byproducts formed from intestinal microorganisms may be called “intestinal microbial metabolites.”
- Intestinal microbial metabolites may also modulate the immune system through impacting the physiology of host cells, gene expression, or both. Specific fermentation pathways carried out by intestinal microorganisms can result in the formation of toxic compounds that have the potential to damage the host epithelium and cause inflammation. In other instances, formation of intestinal microbial metabolites may exacerbate diseases and conditions related to human health.
- one or more embodiments herein relate to a pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite.
- the pharmaceutical formulation may include an effective amount of a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof, wherein the macrocyclic molecule comprises 5 to 20 glycoluril monomers.
- one or more embodiments herein relate to a method of treating a patient with an elevated serum level of an intestinal microbial metabolite.
- the method may include administering a dose of a macrocyclic molecule to the patient with the elevated serum level of the intestinal microbial metabolite.
- the macrocyclic molecule may be selected from the group consisting of a cucurbituril.
- a cucurbituril derivative a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof, and wherein the macrocyclic molecule comprises 5 to 20 glycoluril monomers.
- one or more embodiments herein relate to a method of treating a disease.
- the method may include administering an effective amount of a macrocyclic molecule to a patient suffering from the disease.
- the disease may be selected from the group consisting of a cardiovascular disease, a cerebrovascular disease, a kidney disease, a psychiatric disorder, a gastrointestinal disorder, and a combination thereof.
- the macrocyclic molecule is selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof.
- the biocompatible material may include a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof.
- the biocompatible material may include a solid carrier component selected from the group consisting of polyvinylchloride (PVC), polysulfone (PS), polycthcr sulfone (PES), polyphcnylsulfonc (PPSU), polycthcr ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide, nylon, polystyrene, polyacrylate, polycarbonate, polymer containing acrylonitrile, sodium acrylonitrile metarylsulfonate copolymer (AN69),
- one or more embodiments herein relate to a method of treating a patient having an elevated serum level of an intestinal microbial metabolite.
- the method may include passing blood from the patient to an article or a product containing a biocompatible material.
- the biocompatible material may include a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof.
- the biocompatible material may include a solid carrier component selected from the group consisting of polyvinylchloride (PVC), polysulfone (PS), polyether sulfone (PES), polyphenylsulfone (PPSU), polyether ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide, nylon, polystyrene, polyacrylate, polycarbonate, polymer containing acrylonitrile, sodium acrylonitrile metarylsulfonate copolymer (AN69), polymer containing methylallylsul
- the method may include allowing the intestinal microbial metabolite to contact the macrocyclic molecule, thereby capturing the intestinal microbial metabolite with the cucurbituril in an inclusion complex.
- one or more embodiments herein relate to a molecular composite.
- the molecular composite may include a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof.
- the molecular composite may include an additional macrocyclic molecule selected from the group consisting of a cyclic oligosaccharide, a pillararene, a calixarene, a derivative thereof, and a combination thereof.
- FIG. 1A shows a chemical formula of cucurbituril with “n” number of units, according to one or more embodiments.
- FIG. IB shows a chemical formula of cucurbituril, illustrated with five units of the chemical formula of FIG. 1A, according to one or more embodiments.
- FIG. 2 shows a dialyzer, according to one or more embodiments.
- FIG. 3 shows a dialyzer, according to one or more embodiments.
- a biochemical in the body may be processed by gastrointestinal bacteria to produce a metabolized biochemical, such as one or more intestinal microbial metabolite.
- An intestinal microbial metabolite may be further processed in the liver.
- An intestinal microbial metabolite or a downstream product and/or conjugate thereof may be grouped under the phrase intestinal microbial metabolite.
- Intestinal microbial metabolites have been implicated as exacerbating factors in various diseases and conditions.
- one or more intestinal microbial metabolites may aggravate or deteriorate a disease or a health condition.
- the metabolite may correlate with increased risk, exacerbation, or manifestation of a disease.
- compositions comprising cucurbituril are provided to sequester, capture, or otherwise associate with one or more biomolecules.
- a biomolecule may be removed once captured by the cucurbituril. Methods herein may include removing a captured biomolecule from the body of a patient, for example.
- a biomolecule may include at least one macronutrient that is consumed in the human diet including, but not limited to, a carbohydrate, a protein, a fat, and a vitamin.
- a macronutrient may be broken down by a metabolic process in the gastrointestinal tract of the body, as previously described.
- a biomolecule is an intestinal microbial metabolite.
- a macronutrient such as a protein may include amino acids such as tyrosine, phenylalanine, and tryptophan.
- An amino acid may be a protein-derived amino acid in the diet. Some amino acids are not able to be created by the human body, which are called essential nutrients (such as essential amino acids).
- Suitable examples of other macronutrients include a vitamin including, but not limited to, choline; an acid including, but not limited to, a short chain fatty acid such as acetic acid, propionic acid, and butyric acid, and a bile acid such as taurocholic acid, glycolic acid, deoxycholic acid; carnitine; dietary fiber; and combinations thereof.
- One or more biomolecules such as a macronutrient may be metabolized by intestinal bacteria to produce an intestinal microbial metabolite.
- intestinal microbial metabolites produced from tyrosine, phenylalanine, or tryptophan include, but are not limited to, indole, indolacetic acid, indoxyl sulfate, skatole, trimethylamine, p- cresol, 4-ethyl phenol, phenol, phenol derivative(s), homocysteine, 3-carboxy-4-methyl-5- propyl-2-furanopropionic acid, urofuranic acid(s), hippuric acid, p-hydroxyhippuric acid, and a combination thereof.
- the metabolite when a biomolecule is broken down to a metabolite, the metabolite may be further processed by oxidation, hydrolysis, reduction, glutathione conjugation, sulfation, acetylation, glucuronidation, another known metabolic process, and a combination thereof.
- an intestinal microbial metabolite may be further metabolized in the liver to produce another compound.
- the compound that has been further metabolized may still be called an intestinal microbial metabolite.
- intestinal microbial metabolites that have been further metabolized may include, but are not limited to, indoxyl sulfate, hippuric acid, p-cresyl sulfate, p-cresol glucuronide, 4-ethylphenol sulfate (4EPS), trimethylamine-N trimethylamine-N-oxide (TMAO), and other suitable downstream metabolic products.
- indoxyl sulfate hippuric acid
- p-cresyl sulfate p-cresol glucuronide
- 4EPS 4-ethylphenol sulfate
- TMAO trimethylamine-N trimethylamine-N-oxide
- an elevated serum level of a metabolite when an elevated TMAO level is present in the serum of a patient, the elevated serum TMAO level may correlate with cardiovascular disease.
- an elevated serum 4EPS level may correlate with psychological conditions, such as autism spectrum disorder (ASD).
- an elevated serum indoxyl sulfate and/or p-cresyl sulfate level may correlate with kidney disease, such as chronic kidney disease. Chronic kidney disease may be prevalent in, for example, a dialysis patient.
- Some conventional methods may be used to remove an intestinal microbial metabolite directly from the blood of patients with end-stage renal failure, such as dialysis.
- a protein-bound intestinal microbial metabolite such as indoxyl sulfate and/or p-cresyl sulfate that is bound to albumin, is not removed sufficiently by dialysis to reduce the serum level of the metabolite.
- intestinal microbial metabolite may be difficult to remove from the body by conventional means because of its structure, such as a protein-bound or a conjugate structure.
- free intestinal microbial metabolites (not protein-bound or conjugated) may also be difficult to remove from the body by conventional means.
- intestinal microbial metabolites whether protein-bound or free
- factors that affect dialysis efficiency include size (molecular weight), solubility in water (hydrophilic/hydrophobic), protein binding rate (if any), and volume of distribution.
- intestinal microbial metabolites that have low solubility in water (that are hydrophobic) are more likely to bind to proteins including, but not limited to, albumin.
- intestinal microbial metabolites that have high solubility in water (that are hydrophilic) are less likely to bind to proteins including, but not limited to, albumin.
- the molecular weight of molecules that may be removed by dialysis are up to a size of 10,000 (10 4 ) grams per mole (g/mol) molecular weight.
- dialysis used alone for the removal of molecules with a molecular weight greater than 1 ,000 g/mol may not be as efficient as other techniques. Hemodiafiltration and hemofiltration techniques may remove molecules with a size greater than 10,000 g/mol.
- indoxyl sulfate has a molecular weight of about 213 g/mol and p- cresyl sulfate has a molecular weight of about 210 g/mol (in sodium salt form, or about 188 g/mol as p-cresol sulfate); intestinal microbial metabolites such as these are easily removed by dialysis if not bound to proteins.
- the molecular weight of albumin that is about 66,500 (6.65 x 10 4 ) g/mol (or 66.5 kilodalton) shows that protein-bound intestinal microbial metabolites may be difficult to remove by dialysis alone.
- one or more embodiments of the present disclosure relates to removal of an intestinal microbial metabolite (or a further downstream metabolite) using a macrocyclic compound such as cucurbituril.
- Compositions and methods according to one or more embodiments herein may have fewer side effects and/or greater efficacy compared to conventional compositions and methods to remove a metabolite.
- greater efficacy relates to removing an intestinal microbial metabolite sufficiently to reduce a serum level of the metabolite (whether protein-bound or free).
- compositions and methods to remove a metabolite may include activated carbon, macrocycles (macrocyclic hosts), and uses thereof.
- activated carbon may be used as an oral adsorbent and blood purification device, but it does not allow specific control of the size of the substance that is to be adsorbed.
- Conventional compositions also adsorb many components that arc useful to the body.
- macrocycles cyclodextrins may be used.
- cyclodextrins are reported to have low selectivity and low affinity due to their low binding constant (such as binding constant, Ka, of ⁇ 10 4 M 1 (1/M)) (as reported in Rekharsky, M. V., and Inoue, Y. (1998), Complexation thermodynamics of cyclodextrins. Chem. Rev. 98, 1875-1917. doi: 10.1021/cr970015o).
- cyclodextrin due to the low binding constant, excess concentration of cyclodextrin (and other macrocycles) may be needed to form host-guest complexes with, for example, intestinal microbial metabolites. Furthermore, cyclodextrins and other conventional macrocycles may be nephrotoxic when administered in an unmetabolized form.
- the binding constant (Ka) of cucurbituril is several orders of magnitude greater than those of cyclodcxtrins in aqueous medium (as reported by: Cao, L., Sckutor, M., Zavalij, P. Y., Mlinaric-Majerski, K., Glaser, R., and Isaacs, L. (2014), Cucurbit[7]uril*guest pair with an attomolar dissociation constant; Angew. Chem. Int. Ed. 53, 988-993, doi: 10.1002/anie.201309635; Assaf, K.
- cucurbiturils may be nontoxic and biocompatible (as reported by: Montes-Navajas, P., Gonzalez-Bejar, M., Scaiano, J. C., and Garcia, H. (2009), Cucurbituril complexes cross the cell membrane, Photochem. Photobiol. Sci. 8, 1743-1747, doi: 10.1039/b9pp00041k; Hettiarachchi, G., Nguyen, D., Wu, J., Lucas, D., Ma, D., Isaacs, L., et al.
- cucurbituril is derived from the cyclic molecule’s resemblance with a pumpkin of the family Cucurbitaceae .
- cucurbituril When viewed thrcc-dimcnsionally, cucurbituril has a pumpkin-like shape with an exterior band and an interior cavity. Cucurbituril has no bottom and no top. Thus, cucurbituril has an interior cavity that is accessible from the top and the bottom.
- the oxygen atoms in cucurbituril are located along the edges of the exterior band and are tilted inwards, forming a partly enclosed interior cavity.
- the exterior of cucurbituril is made up of a band of glycoluril molecules that are linked by methylene bridges.
- the interior cavity of cucurbituril may capture a molecule within the interior cavity.
- the molecule or portion thereof may be called a “guest” where the cucurbituril is the “host.”
- the cucurbituril molecule may function as a macrocyclic host in host-guest chemistry and supramolecular chemistry.
- an inclusion complex (also known as an inclusion compound) is formed from a cucurbituril and a molecule that is captured in the cucurbituril.
- the interior cavity of cucurbituril is hydrophobic. Because the interior cavity of cucurbituril may be hydrophobic, the guest molecule may easily be incorporated into the interior cavity when the guest molecule is also hydrophobic.
- a guest molecule is an intestinal microbial metabolite.
- the interior cavity of cucurbituril is lipophilic. Because the interior cavity of cucurbituril may be lipophilic, the guest molecule may easily be incorporated into the interior cavity when the guest molecule is also lipophilic. Thus, a guest molecule that is hydrophobic, lipophilic, or both hydrophobic and lipophilic may be water insoluble.
- n is from 5 to 20 glycoluril monomers.
- FIG. IB shows cucurbituril having 5 glycoluril monomers.
- a composition comprising cucurbituril may include cucurbituril molecules having different n number of glycoluril monomers.
- cucurbituril is described as cucurbit[n]uril (or CB[n] or CBn), where n is the number of glycoluril monomers.
- the interior cavity in cucurbituril is from about 4.4 angstroms (A) to about 7.3 A in diameter.
- the cucurbituril may have an interior cavity that is suitably sized for a guest molecule or a portion of a guest molecule. Meaning, the formation of the inclusion complex of cucurbituril and the guest molecule depends on the size of the cucurbituril interior cavity. [0043]
- the exterior dimensions of the cucurbituril are slightly larger than the interior cavity size. For example, a cucurbituril having n-6 has a height of about 9.1 angstroms (A) and an outer diameter of about 5.8 A, while having an inner diameter of about 3.9 A.
- cucurbituril may range from about 830 to about 3,320 grams per mole (g/mol) (or from about 0.83 to about 3.32 kilodalton (KDa)). In one or more embodiments, the cucurbituril may be in a range of from about 0.5 to about 5 KDa. Thus, cucurbituril may be in a range having a lower limit of any of 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, or 3.5 KDa, and an upper limit of any of 1.0, 1.5, 2.0. 2.5, 3.0, 3.5, 4.0, 4.5, 5.0 KDa, where any lower limit may be combined with any mathematically allowed upper limit.
- cucurbituril One factor that is included in the size of cucurbituril is the n number of glycoluril monomers. For example, a single glycoluril monomer with two methylene bridges has a molecular weight of about 166 g/mol. Another factor that is included in the size of the cucurbituril is whether the cucurbituril is a conjugate, derivative, or another suitable form of cucurbituril.
- the cucurbituril is resistant to acidic pH.
- Resistant to acidic pH means that the cucurbituril retains its function at acidic pH, which is to trap a molecule or portion thereof as a guest molecule within the interior cavity without, for example, decomposing or breaking apart.
- An acidic pH may be less than 7.0. such as a pH having a lower limit of any of 0.1, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 3.5, and an upper limit of any of 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, and 7.0, where any lower limit may be combined with any mathematically allowed upper limit.
- Acidic pH may be representative of a gut, stomach, intestine, colon, or other gastrointestinal location.
- Acidic physiological pH may be from 1.0 to 4.0, such as from 1.5 to 3.5.
- Such areas of the body are known to include strong acids such as hydrochloric acid (HC1).
- Other compounds may be mixed with HC1 in an acidic mixture within the stomach or gut including, but not limited to, compounds such as a salt, an enzyme, and a combination thereof.
- a salt may include, but is not limited to potassium chloride, sodium chloride, and a combination thereof. These acidic mixtures may also have an acidic pH.
- the cucurbituril may be in a form selected from the group consisting of a crystalline product, an amorphous powder product, a syrup, a gel, and a combination thereof.
- the cucurbituril may be a commercially available product or may be produced by a conventional method.
- a composition comprising cucurbituril herein is a pharmaceutical formulation.
- a pharmaceutical formulation herein includes cucurbituril as an active ingredient.
- a pharmaceutical formulation may include more than one active ingredient. For example, depending on what disease or health condition that the pharmaceutical formulation is used to treat, there may be one or more additional active ingredient.
- active ingredients in addition to cucurbituril include, but are not limited to: sodium polystyrene sulfonate and/or calcium polystyrene sulfonate corresponding with hyperpotassemia, chronic kidney disease, dialysis, and a combination thereof; cholestyramine corresponding with dyslipidemia, diarrhea (such as due to inhibition of endotoxin activity), vitamin D3 overdose, and a combination thereof; one or more of sevelamer hydrochloride, lanthanum carbonate hydrate, bixaromer, ferric citrate hydrate preparations, precipitated calcium carbonate, and sucrooxy iron hydroxide corresponding to hyperpotassemia, chronic kidney disease, dialysis, and combinations thereof; and activated charcoal corresponding to chronic kidney disease and/or acute drug poisoning.
- compositions herein include different forms of cucurbituril.
- cucurbituril herein may refer to cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, or a combination thereof.
- a cucurbituril conjugate may include a chemically modified cucurbituril where one or more carbonyl carbon of cucurbituril is an attachment point for another molecule or chemical moiety.
- a cucurbituril conjugate may include an ester linkage, or other suitable linkage known in the ail to chemically and physically bind the cucurbituril.
- a pharmaceutical formulation herein includes an inactive ingredient.
- a pharmaceutical formulation herein may include one or more component that is orally administered.
- a pharmaceutical formulation comprising cucurbituril may include glycoluril, formaldehyde, and a combination thereof.
- a pharmaceutical formulation substantially does not include formaldehyde. Formaldehyde is generally harmful to the body of living animals including humans, and the pharmaceutical formulation including less formaldehyde is preferable.
- the cucurbituril may be formed from a formaldehyde-free reaction subjecting to react glycoluril monomers with a methylene bridging agent instead of formaldehyde or its precursor in the presence of an acid.
- the methylene bridging agent can be a dialkoxymethane, preferably diethoxymethane or dipropoxymethane.
- Another formaldehyde-free reaction can be a reaction of a fully alkoxy methylated glycoluril with unsubstituted glycoluril in the presence of an acid.
- the pharmaceutical formulation comprising cucurbituril is in a suitable dosage form for oral administration.
- Oral administration is where a substance is taken through the mouth.
- suitable dosage forms of a pharmaceutical formulation comprising cucurbituril include, but are not limited to, a tablet, a chew (a dissolvable solid or tablet), a capsule (hard capsule, soft capsule, gel capsule, microcapsule, or chewable capsule), a liquid, a gel, a powder, a granule (such as a fine granule), a round, a pastille, an osmotic delivery system, a decoction, an elixir, an electuary, an emulsion, an effervescent, a solution, a suspension, a tincture, a syrup, a food product including, but not limited to, a drink, and a combination thereof.
- the dosage form may be time-release, extended-release, or sustained release.
- the cucurbituril may be released in the colon to adsorb intestinal microbial metabolites from enteric bacteria.
- cellulase derivatives such as cellulase acetate phthalate (CAP) and cellulose hydroxy propyl methyl phthalate may be used.
- CAP cellulase acetate phthalate
- cellulose hydroxy propyl methyl phthalate may be used.
- a dosage form that dissolves in alkaline intestinal juice and not, for example, in acidic gastric juice
- One or more embodiments of the present disclosure relate to a method of administering a composition comprising cucurbituril to a patient in need thereof.
- the composition comprising cucurbituril may be a pharmaceutical composition.
- the method may include administering a dose of cucurbituril by oral administration or by other means to a gastrointestinal tract, such as by a feeding tube.
- the method may include administering a single dose or multiple doses in an effective amount to treat a patient having an elevated serum level of an intestinal microbial metabolite.
- An effective amount reduces an elevated level (concentration) of the intestinal microbial metabolite to a safe or normal level of the intestinal microbial metabolite, where concentration may be measured in a patient’s serum.
- concentration concentration
- the effective dose and number of doses of cucurbituril may vary depending on the type of administration, the patient’s age, body weight, nature, or severity of symptoms to be treated, overall health, other health conditions, additional medicines, and other factors.
- a maximum allowable dose for a human is up to about 1,000 milligrams per kilogram of body weight (mg/kg/body weight) per day of cucurbituril that is orally administered.
- one or more embodiments of the method include treating a patient having an elevated scrum level of an intestinal microbial metabolite.
- indoxyl sulfate produced from indole in intestine
- P-cresyl sulfate (produced from phenol in intestine) has a normal concentration of about 1.9 mg/L (SD: 1.3), a mean uremic concentration of about 20.9 mg/L (SD: 12.2), a greatest uremic concentration of about 41 mg/L (SD: 13.3).
- the method may include allowing the cucurbituril (or derivative, etc.) to associate with the intestinal microbial metabolite, thereby capturing the intestinal microbial metabolite with the cucurbituril.
- an inclusion complex may be formed by inclusion of the intestinal microbial metabolite in the cucurbituril (as a host-guest complex).
- a concentration (level) of an intestinal microbial metabolite in the gastrointestinal tract and serum are thought to decrease to a normal or a healthy level as compared to an elevated level, which may suppress the progression of various diseases and human health conditions.
- the method includes removing the intestinal microbial metabolite from the patient.
- Removing the intestinal microbial metabolite may include removing an inclusion complex (metabolite with cucurbituril), unused cucurbituril that may not be part of an inclusion complex, as well as free intestinal microbial metabolite.
- the patient to be treated may be suffering from a disease, a disorder, or have a condition that is exacerbated by the elevated serum level of the intestinal microbial metabolite.
- the patient’s condition may include an elevated serum level of an intestinal microbial metabolite.
- the condition may be selected from the group consisting of a cardiovascular disease, a cerebrovascular disease, a kidney disease, a psychiatric disorder, a gastrointestinal disorder, and other metabolic diseases and disorders, and a combination thereof.
- the cardiovascular disease and/or the cerebrovascular disease is selected from the group consisting of coronary heart disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism, stroke, cerebral infarction, and a combination thereof.
- An example intestinal microbial metabolite that exacerbates a cardiovascular disease and/or cerebrovascular disease includes trimethylamine N-oxide.
- Phosphatidylcholine in food is metabolized to trimethylamine N (TMA) by intestinal bacteria.
- TMA trimethylamine N
- TMAO trimethylamine N-oxide
- FMA3 flavin-containing monooxygenase 3
- the kidney disease is selected from the group consisting of chronic kidney disease, IgA nephropathy, and a combination thereof.
- An example intestinal microbial metabolite that exacerbates a kidney disease includes indoxyl sulfate, p-cresyl sulfate, and combinations thereof.
- Indoxyl sulfate induces renal tubular cell injury and cell death through production of oxidative stress, among other things.
- indoxyl sulfate stimulates renal fibrosis through TGF-bcta overexpression and activates mesangial cell proliferation.
- P-cresyl sulfate also causes renal tubular cell damage by inducing oxidative stress, among other things.
- the psychiatric disorder is selected from the group consisting of an autism spectrum disorder, an anxiety disorder, and a combination thereof.
- An example intestinal microbial metabolite that exacerbates a psychiatric disorder includes 4-ethylphenyl sulfate (4EPS).
- 4-Ethylphenyl sulfate (4EPS) is produced when tyrosine is metabolized by intestinal bacteria to 4-ethylphenol, which is then sulfate conjugated in liver.
- 4-Ethylphenol (4EP) and 4-ethylphenyl sulfate (4EPS) prevent oligodendrocyte maturation, inhibit neuronal myelin formation, and decrease connectivity in the brain, among other things. Such changes may be strong in anxiety disorders.
- the gastrointestinal disorder is selected from the group consisting of irritable bowel disease, irritable bowel syndrome, intestinal permeability, colon cancer, gastrointestinal cancer, and a combination thereof.
- An example intestinal microbial metabolite that exacerbates a gastrointestinal disorder includes skatole (produced from dietary tryptophan, metabolized by intestinal microbes) and tryptamine.
- Skatole plays a role in the disturbance of intestinal homeostasis and in the development of intestinal bowel disease via inhibition of CYP11A1 expression and glucocorticoid production, among other things.
- Tryptamine is a ligand for trace amine- associated receptors and potentiates the inhibitory effect of serotonin that is involved in intestinal bowel disease, among other things.
- SCFA short chain fatty acid
- Short chain fatty acids include, but are not limited to, propionic acid, butyric acid, valeric acid, and combinations thereof.
- Short chain fatty acids are produced in various parts of the intestinal tract.
- concentrations of acetic acid, propionic acid, and total organic acids in the feces of irritable bowel syndrome patients are greater than those of patients without irritable bowel syndrome.
- Other conditions include, but are not limited to dementia, obesity, diabetes, dyslipidemia, malignancies, allergies, and chronic inflammatory diseases.
- Examples of an intestinal microbial metabolite that exacerbates dementia include, but are not limited to ammonia, p-cresol, isovaleric acid, indole, butyric acid, phenol, skatole.
- Examples of intestinal microbial metabolites that exacerbate diabetes, autoimmune disease(s), and infections are short chain fatty acids.
- Other intestinal microbial metabolites that may contribute to diabetes include trimethylamine and trimethylamine oxide.
- Other conditions may include liver cancer, exacerbated by an intestinal microbial metabolite such as secondary bile acids.
- a material having a composition comprising cucurbituril is biocompatible or blood-compatible, and an article at least partially formed from the material may be used in biological and medical arts.
- the article may include from about 0.1 to about 50 weight % of macrocyclic molecule (cucurbituril).
- Biocompatible means an ability to act and perform without impairing basic immunological functions of the body or causing injurious, negative physiological, or toxic reactions.
- Bood- compatiblc means a feature suitable for direct contact with blood without causing an injurious, negative physiological, allergic, or toxic reaction.
- ISO 10993-4 is a standardized method to test for blood compatibility.
- thrombogenicity Under this standard, thrombogenicity, blood coagulation, platelets, hematologic items, and complement activation systems are evaluated. Saline extracts are used for hemolytic testing, immunologic testing (through complement activation), and devices in direct contact with blood. Hemolysis studies such as thrombogenicity testing should be performed using direct and indirect methods; thrombogenicity should be evaluated as part of safety studies performed in relevant animal models. As an alternative, a 4-hour canine venous heparinization model can be used to evaluate thrombogenicity.
- a product to be used in biological and medical arts may be formed from the article.
- An example of the product is a dialysis membrane.
- a method is provided that includes removing an intestinal microbial metabolite from the body of a dialysis patient using the dialysis membrane.
- the dialysis membrane may adsorb an intestinal microbial metabolite that may be free or bound to a protein.
- the intestinal microbial metabolite may be adsorbed during a dialysis process.
- the article according to one or more embodiments herein further comprises a solid carrier component.
- the solid carrier component may be a constituent of the composition of the material comprising cucurbituril and may be another component of the article than a component made of the material comprising cucurbituril.
- the weight ratio between the macrocyclic molecule (cucurbituril) and the solid carrier component may be from about 1:1000 to about 1:1.
- the dialysis membrane may include a conventional dialysis membrane as the solid carrier component.
- a conventional dialysis membrane as the solid carrier component.
- intestinal microbial metabolites may be removed by size as well as adsorption.
- a coating of cucurbituril on a surface of the conventional dialysis membrane allows adsorption of intestinal microbial metabolites and the conventional dialysis membrane allows removal of components by size.
- cucurbituril may be used to enhance adsorption capacity of the dialysis membrane.
- the solid carrier component may comprise a polymer or other suitable solid carrier.
- Suitable examples of the polymer for the solid carrier component include, but are not limited to, polyvinylchloride (PVC), polysulfone (PS), polyether sulfone (PES), polyphenylsulfone (PPSU), polyether ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide including, but not limited to, nylon, polystyrene, polyacrylate, polycarbonate, polymer containing acrylonitrile including, but not limited to, sodium acrylonitrile metarylsulfonate copolymer
- one or more additional component may be included in the article.
- one or more additional components may be included in the article.
- the solid carrier component may be from about 0.1 to about 50 weight % of the total article.
- the cucurbituril may be affixed to the solid carrier component.
- the cucurbituril may be physically or chemically mixed, bound, and/or associated with the solid carrier component.
- the solid carrier component is a polymer
- the cucurbituril and the polymer may be cross-linked or otherwise attached to form a polymer including cucurbituril.
- the article has a form that may include but is not limited to a sheet, a membrane, a hollow fiber, a porous material, a particle, a foam, a textile, a granule, a non-woven, a gel, and a combination thereof.
- the article may have a surface that includes cucurbituril.
- the cucurbituril may be exposed at the surface of the article. That is, the cucurbituril in the article may host small molecule guests to form an inclusion complex with an intestinal microbial metabolite and cucurbituril at the surface.
- the surface of the article may be smooth, porous, semiporous, or a combination thereof.
- the article may include one or more layer that cucurbituril may be embedded in or may be exposed at the surface of the one or more layer, to an extent that a small molecule such as an intestinal microbial metabolite is accessible to the cucurbituril of each layer.
- the article according to one or more embodiments may be formed by a method comprising one of coating, mixing, layering, and a combination thereof.
- the article according to one or more embodiments may be formed by applying a coating comprising cucurbituril on a surface of a substrate comprising the solid carrier component.
- the coating may cover a part or whole of the substrate.
- Traditional coating techniques that are known in the art may be used.
- the article according to one or more embodiments may be formed of a mixture of cucurbituril and the solid carrier component. Traditional mixing techniques that are known in the art may be used.
- the article according to one or more embodiments may be formed by layering a plurality of layers.
- the composition formed of each of the layers may be same or different.
- traditional layering techniques that are known in the art may be used. Layering techniques include but are not limited to a layer-by-layer application.
- a product is provided that includes an article according to one or more embodiments.
- the product may be a blood-compatible adsorbent.
- the blood-compatible adsorbent may be a porous membrane such as a dialysis membrane comprising the article according to one or more embodiments.
- the cucurbituril contained in the article may be exposed on at least one surface of the dialysis membrane so that the cucurbituril is able to host a toxic substance in a fluid.
- the product may be made from, in whole or in part, the article according to one or more embodiments.
- the article may also be on a portion of or the entirety of the product.
- the product when the product is a catheter, the article may be provided on part of the catheter or the entire body of the catheter. As well, the catheter may be made from the article.
- the product may be tailored for an application depending on where the cucurbituril and adsorption effects are needed.
- a dialysis apparatus comprising an article herein.
- a dialysis apparatus may include a product comprising an article having cucurbituril and a solid carrier component.
- One or more embodiments of a composition comprising cucurbituril and a method of use herein may be associated with an extracorporeal treatment.
- the dialysis apparatus may be a hemodialysis apparatus. This type of dialysis is sometimes called hemodialysis and removes extracorporeal waste and frees water from the blood, for example, when kidneys are in a state of failure in a patient.
- Other extracorporeal treatments include peritoneal dialysis, and adsorption with sorbents, such as charcoal or another adsorbent, and filtration that are suitable for use with one or more embodiments herein.
- an intestinal microbial metabolite in serum may be excreted via the kidneys with urine or by other biological mechanisms.
- an intestinal microbial metabolite may remain in the patient’s blood, to be removed by dialysis.
- the intestinal microbial metabolite may be difficult to remove when bound to a protein, such as albumin.
- one or more additional components may be added to the blood of a patient to separate a protein (such as albumin) from a metabolite during dialysis.
- conventional methods of separation may be inefficient, may increase general dosage of medications for a patient, and may decrease the patient’ s quality of life compared to one or more embodiments of a dialyzer herein and methods of use.
- a protein-bound intestinal microbial metabolite may be efficiently removed with articles and products described herein without administering medicine, or an additional medicine that disrupts the protein-metabolite complex (inclusion complex), to a patient in need of dialysis.
- an intestinal microbial metabolite present in serum may be in a protein-bound form. This is because the intestinal microbial metabolite alone may have poor or low water solubility (is hydrophobic).
- transport of the metabolite may occur in aqueous medium, serum, blood, and other biological fluids via the carrier protein.
- the protein that binds the intestinal microbial metabolite includes but is not limited to albumin.
- An intestinal microbial metabolite that is bound to a protein has a larger molecular mass than the metabolite alone that is not protein-bound.
- a low molecular mass intestinal microbial metabolite may be less than 50 g/mol.
- An average molecular mass may be between 50 and 5,000 g/mol.
- a large molecular mass may be greater than 5,000 g/mol.
- a protein-bound intestinal microbial metabolite may fall within the large molecular mass range.
- One or more embodiments of the present disclosure includes removing a proteinbound intestinal microbial metabolite from serum.
- the protein-bound intestinal microbial metabolite may be effectively removed even at sizes that do not readily diffuse across a dialysis membrane, such as a (large) molar mass from about 65,000 to 70,000, which is about the size of albumin present in serum and a metabolite bound thereto.
- FIG. 2 shows a cucurbituril-containing dialyzer 200 with a cucurbituril-containing dialysis bag 202, according to one or more embodiments.
- the cucurbituril-containing dialyzer is depicted as a simplified version for clarity. A person of ordinary skill in the art would appreciate variations of dialyzers that are known in the art.
- blood is introduced into a blood inlet 210 where it passes to the blood compartment 206. From the blood compartment, the blood passes to the blood outlet 212, through which the blood exits the cucurbituril-containing dialyzer 200.
- dialysate is introduced into a dialysate inlet 214 where it passes to the dialysate compartment 208. From the dialysate compartment, the dialysate passes to the dialysate outlet 216, through which the dialysate exits the cucurbituril-containing dialyzer 200.
- the dialysis membrane includes or is made from an article (containing cucurbituril) according to one or more embodiments and is called a cucurbituril-containing dialysis membrane 204.
- the cucurbituril-containing dialysis membrane separates the blood compartment 206 from the dialysate compartment 208.
- the cucurbituril-containing dialysis membrane 204 allows free intestinal microbial metabolite 220 (unbound to a protein 222) to pass over the cucurbituril-containing dialysis membrane 204.
- the free intestinal microbial metabolite 220 may pass from the dialysate compartment 208 through the dialysate outlet 216 and exit the dialyzer 200 for further processing and/or removing steps.
- the dialysate may be recycled and reintroduced, or removed and fresh dialysate may be introduced into the dialysate inlet 214.
- a protein-bound intestinal microbial metabolite 224 may not pass through a dialysis membrane because the holes in the membrane are too small for the protein-bound intestinal microbial metabolite to pass through.
- the cucurbituril-containing dialysis membrane 204 may also trap an intestinal microbial metabolite that is protein-bound. In other instances, the cucurbituril-containing dialysis membrane 204 may trap a free intestinal microbial metabolite.
- the cucurbituril in the cucurbituril-containing dialysis membrane 204 associates with a protein-bound intestinal microbial metabolite 224, the binding affinity of the metabolite for the protein decreases from its protein-bound state to an extent that the metabolite may separate from the protein.
- cucurbituril in the cucurbituril-containing dialysis membrane may bind with the free intestinal microbial metabolite to form an inclusion complex 207.
- the cucurbituril in the cucurbituril-containing dialysis membrane may retain a protein-bound intestinal microbial metabolite without separation of the metabolite from the protein. Meaning, an inclusion complex may be formed between the cucurbituril in the membrane and the protein-bound metabolite. Nonetheless, even in this case the intestinal microbial metabolite may be efficiently captured for later removal in the blood compartment of a dialyzer according to one or more embodiments.
- Removing the free metabolite may occur via the dialysate outlet during filtration.
- Removing the inclusion complex of the intestinal microbial metabolite (protein-bound or free) and the cucurbituril may occur by removing the dialyzer from the apparatus and cither replacing with a new dialyzer or flushing the dialyzer with an appropriate fluid to remove the intestinal microbial metabolite that may be bound to the cucurbituril in an inclusion complex.
- the cucurbituril-containing dialysis membrane may be integrated into any suitable portion of the dialysis apparatus that contacts blood or serum, including, but not limited to, a bag, a blood cap, a fiber membrane, and a combination thereof. As shown in FIG. 2, the cucurbituril-containing dialysis membrane may be included in a dialyzer. Alternatively, or in addition, the cucurbituril-containing dialysis membrane may be a separate bag or a cartridge that is upstream of a dialyzer.
- a method of treating a patient having an elevated serum level of a microbial metabolite may include the following steps. First, the method may include identifying an elevated serum level of an intestinal microbial metabolite in a patient. Second, the method may include passing blood from the patient to a product containing an article. Third, the method may include allowing the intestinal microbial metabolite to contact the cucurbituril, thereby capturing the intestinal microbial metabolite with the cucurbituril in an inclusion complex. Fourth, the method may include removing the captured microbial metabolite, thereby forming an inclusion complex and an intestinal microbial metabolite- depleted blood. The method may include passing the metabolite-depleted blood back to the patient.
- the article is effective when the metabolite to be removed is bound to a protein as carrier protein.
- the protein may be a serum protein including, but not limited to albumin (such as human albumin), oci-acid glycoprotein, alpha 1-acid glycoprotein (AGP), a lipoprotein, an immunoglobulin, and mixtures thereof.
- albumin such as human albumin
- AGP alpha 1-acid glycoprotein
- the article is effective when the metabolite to be removed is free, or is not protein bound.
- An amount of intestinal microbial metabolite in serum that may be removed based on a safe dose may vary based on the individual’s health condition. For example, in the case of indoxyl sulfate, the average concentration in healthy subjects is less than 10 micromolar (pM), but in patients with end-stage chronic renal failure, the average concentration is about 250 pM and may reach up to about 550 pM (117.27 mg/L for a molecular weight of 213.21 g/mol).
- a 60 kilogram (kg) person has a blood volume of approximately 4.6 liters (L), which means that about 539 milligrams (mg) of cucurbituril may be present in the blood according to the aforementioned concentration(s).
- L blood volume
- amino acids and vitamins may also be adsorbed. Such amino acids and vitamins may also be replenished in the patient.
- a composition called a “molecular composite” that comprises cucurbituril and one or more macrocyclic compound in addition to the cucurbituril.
- the molecular composite may be biocompatible.
- the molecular composite is an adsorbent for the removal of a protein-bound intestinal microbial metabolite. Methods herein may be used to support an extracorporeal treatment including dialysis (or hemodialysis) with a dialyzer, filtration with a hemofiltration apparatus, and other techniques that are known to one of ordinary skill in the art.
- the one or more macrocyclic compound in addition to cucurbituril may include a cyclic oligosaccharide such as a pillararene, a calixarene, a derivative thereof, and a combination thereof.
- an intestinal microbial metabolite may bind to a protein in human blood and serum.
- the metabolite may also bind to a protein in other biological fluids such as interstitial fluid, peritoneal fluid, third space fluid, including cerebrospinal fluid, gastrointestinal tract fluid, urinary tract fluid, gland fluid, cavity fluid, and other biological liquids.
- interstitial fluid such as interstitial fluid, peritoneal fluid, third space fluid, including cerebrospinal fluid, gastrointestinal tract fluid, urinary tract fluid, gland fluid, cavity fluid, and other biological liquids.
- this metabolite may be a toxic substance.
- One of ordinary skill in the art would appreciate other toxic substances that may be present in serum.
- a displacer is a substance that may bind to a protein, such as a protein in human blood or serum, and displace a toxic substance such as an intestinal microbial metabolite.
- a displacer may be natural, such as bilirubin, and/or albumin, or it may be synthetic such as acetaminophen.
- a displacer may competitively bind to a protein while displacing a metabolite that was previously bound to the protein.
- the cucurbituril may be mixed in a molecular composite that is added to pre-dialysis blood.
- Macrocyclic components in the molecular composite may form an inclusion complex with the toxic substance such as an intestinal microbial metabolite.
- the inclusion complex may be removed by dialysis, filtration, or another suitable extracorporeal treatment of removal including, but not limited to, extracorporeal renal replacement therapy.
- FIG. 3 shows a molecular composite dialyzer 300 with a molecular composite dialysis bag 302, according to one or more embodiments herein.
- the molecular composite dialyzer 300 includes a molecular composite distributor 303 that is coupled to the blood compartment 206.
- the molecular composite distributor 303 is affixed to the blood compartment.
- a molecular composite distributor may be accessible to the blood compartment by a conduit such as a tube or a pipe.
- a molecular composite distributor may also be a means of introducing a molecular composite into the blood compartment such as an injection.
- the molecular composite may also be a combination of the above-mentioned molecular composites.
- the dialysis membrane 304 may be a conventional dialysis membrane or it may be a cucurbituril-containing dialysis membrane (as shown in FIG. 2).
- blood is introduced into a blood inlet 210 where it passes to the blood compartment 206. From the blood compartment, the blood passes to the blood outlet 212through which the blood exits the molecular composite dialyzer 300.
- dialysate is introduced into a dialysate inlet 214 where it passes to the dialysate compartment 208. From the dialysate compartment, the dialysate passes to the dialysate outlet 216 through which the dialysate exits the molecular composite dialyzer 300.
- the cucurbituril 305 in the molecular composite may intermingle with a protein-bound intestinal microbial metabolite 224 or a free intestinal microbial metabolite (not protein-bound).
- the protein may dissociate from the captured toxic substance upon binding and formation of an inclusion complex.
- an inclusion complex 306 may be formed between the cucurbituril (and/or molecular composite) and the toxic substance or the intestinal microbial metabolite.
- the inclusion complex 306 is much smaller than the protein-bound intestinal microbial metabolite 224 so that it can pass through the pore of the dialysis membrane 304.
- the inclusion complex formed of at least one of cucurbituril formed from 5 to 10 glycoluril monomers is especially preferable with its size.
- the inclusion complex 306 formed in the blood compailment 206 may pass through the dialysis membrane 304 to the dialysate compartment 208 following the concentration gradient.
- the method includes removing the captured toxic substances from the blood of a patient.
- a free intestinal microbial metabolite may pass through the dialysis membrane 304 to the dialysate compartment 208.
- Inclusion complexes including cucurbituril and a toxic substance such as an intestinal microbial metabolite may pass through the dialysis membrane 304 (in the case of, for example, hemodiafiltration where this process removes inclusion complexes with proteins such as albumin).
- the intestinal microbial metabolite may pass from the molecular composite dialyzer 300 via the dialysate outlet 216 and exit the system.
- the method may include flushing the dialysate compartment with further dialysate, thereby removing the toxic substances from the dialyzer.
- Benefits of the method of introducing the molecular composite in pre-dialysis blood include an increased efficiency of protein-bound metabolite removal compared to without the molecular composite. Toxicity is reduced (and safety is improved) compared to when using bilirubin, cyclodextrin or other conventional macrocycle, or another compound that displaces intestinal microbial metabolites bound to albumin. Cost is also reduced; for example, conventional displacement methods such as administering albumin is expensive and impractical on a daily basis, whereas cucurbituril is lower cost. Cucurbituril is also more efficient in binding intestinal microbial metabolites compared to cyclodextrin (and other conventional macrocycles). [00119] Unless defined otherwise, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art to which these systems, apparatuses, methods, processes, and compositions belong.
- this term may mean that there can be a variance in value of up to ⁇ 10%, of up to 5%, of up to 2%, of up to 1%, of up to 0.5%, of up to 0.1%, or up to 0.01%.
- substantially refers to a majority of, or mostly, as in at least about 50%. 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.
- Ranges may be expressed as from about one particular value to about another particular value, inclusive. When such a range is expressed, it is to be understood that another embodiment is from the one particular value to the other particular value, along with all particular values and combinations thereof within the range.
Abstract
A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite includes an effective amount of cucurbituril. A method of treating a patient with an elevated serum level of an intestinal microbial metabolite and a method of treating a disease includes administering a dose of cucurbituril. A product and a molecular composite includes cucurbituril.
Description
CUCURBITURIL COMPOSITIONS, PRODUCTS, AND METHODS OF USE
BACKGROUND
[0001] Human intestinal microbiota include microorganisms such as bacteria that inhabit and maintain homeostasis of the gastrointestinal tract. These microorganisms contribute to the symbiotic ecosystem of the gastrointestinal tract. One benefit of the symbiosis is the metabolic activity of the microorganisms on exogenous and endogenous substrates, forming nutrients that arc useable by the human host.
[0002] The presence of diverse metabolic activity in the human gastrointestinal tract allows the intestinal microbiota to fill available ecological niches and competitively inhibit colonization by pathogens. The gastrointestinal tract may have elevated concentrations of mostly acidic fermentation byproducts compared to other areas of the human body. These elevated concentrations of byproducts may reduce pH locally to create an inhospitable environment for pathogens. The gastrointestinal tract metabolites and byproducts formed from intestinal microorganisms may be called “intestinal microbial metabolites.”
[0003] Intestinal microbial metabolites may also modulate the immune system through impacting the physiology of host cells, gene expression, or both. Specific fermentation pathways carried out by intestinal microorganisms can result in the formation of toxic compounds that have the potential to damage the host epithelium and cause inflammation. In other instances, formation of intestinal microbial metabolites may exacerbate diseases and conditions related to human health.
SUMMARY
[0004] This summary is provided to introduce a selection of concepts that are further described below in the detailed description. This summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used as an aid in limiting the scope of the claimed subject matter.
[0005] In one aspect, one or more embodiments herein relate to a pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial
metabolite. The pharmaceutical formulation may include an effective amount of a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof, wherein the macrocyclic molecule comprises 5 to 20 glycoluril monomers.
[0006] In another aspect, one or more embodiments herein relate to a method of treating a patient with an elevated serum level of an intestinal microbial metabolite. The method may include administering a dose of a macrocyclic molecule to the patient with the elevated serum level of the intestinal microbial metabolite. The macrocyclic molecule may be selected from the group consisting of a cucurbituril. a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof, and wherein the macrocyclic molecule comprises 5 to 20 glycoluril monomers.
[0007] In another aspect, one or more embodiments herein relate to a method of treating a disease. The method may include administering an effective amount of a macrocyclic molecule to a patient suffering from the disease. The disease may be selected from the group consisting of a cardiovascular disease, a cerebrovascular disease, a kidney disease, a psychiatric disorder, a gastrointestinal disorder, and a combination thereof. The macrocyclic molecule is selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof.
[0008] In another aspect, one or more embodiments herein relate to a biocompatible material. The biocompatible material may include a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof. The biocompatible material may include a solid carrier component
selected from the group consisting of polyvinylchloride (PVC), polysulfone (PS), polycthcr sulfone (PES), polyphcnylsulfonc (PPSU), polycthcr ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide, nylon, polystyrene, polyacrylate, polycarbonate, polymer containing acrylonitrile, sodium acrylonitrile metarylsulfonate copolymer (AN69), polymer containing methylallylsulfonate salt, cellulose triacetate (CTA), a copolymer thereof, and a combination thereof.
[0009] In another aspect, one or more embodiments herein relate to a method of treating a patient having an elevated serum level of an intestinal microbial metabolite. The method may include passing blood from the patient to an article or a product containing a biocompatible material. The biocompatible material may include a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof. The biocompatible material may include a solid carrier component selected from the group consisting of polyvinylchloride (PVC), polysulfone (PS), polyether sulfone (PES), polyphenylsulfone (PPSU), polyether ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide, nylon, polystyrene, polyacrylate, polycarbonate, polymer containing acrylonitrile, sodium acrylonitrile metarylsulfonate copolymer (AN69), polymer containing methylallylsulfonate salt, cellulose triacetate (CTA), a copolymer thereof, and a combination thereof. The method may include allowing the intestinal microbial metabolite to contact the macrocyclic molecule, thereby capturing the intestinal microbial metabolite with the cucurbituril in an inclusion complex.
[0010] In another aspect, one or more embodiments herein relate to a molecular composite.
The molecular composite may include a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof. The molecular composite may include an additional macrocyclic molecule selected from the group consisting of a cyclic oligosaccharide, a pillararene, a calixarene, a derivative thereof, and a combination thereof.
[0011] Other aspects and advantages of the claimed subject matter will be apparent from the following description and the appended claims.
BRIEF DESCRIPTION OF DRAWINGS
[0012] Specific embodiments of the disclosed technology will now be described in detail with reference to the accompanying figures. Where the figures include like elements between them, the elements are denoted by like reference numerals. They may be differentiated by letters appended to reference numerals.
[0013] FIG. 1A shows a chemical formula of cucurbituril with “n” number of units, according to one or more embodiments.
[0014] FIG. IB shows a chemical formula of cucurbituril, illustrated with five units of the chemical formula of FIG. 1A, according to one or more embodiments.
[0015] FIG. 2 shows a dialyzer, according to one or more embodiments.
[0016] FIG. 3 shows a dialyzer, according to one or more embodiments.
DETAILED DESCRIPTION
[0017] In the following detailed description of embodiments of the disclosure, numerous specific details arc set forth to provide a more thorough understanding of the disclosure. However, it will be apparent to one of ordinary skill in the art that the disclosure may be practiced without these specific details. In other instances, well-known features have not been described in detail to avoid unnecessarily complicating the description.
[0018] A biochemical in the body may be processed by gastrointestinal bacteria to produce a metabolized biochemical, such as one or more intestinal microbial metabolite. An intestinal microbial metabolite may be further processed in the liver. An intestinal microbial metabolite or a downstream product and/or conjugate thereof (including, but not limited to those formed in the liver) may be grouped under the phrase intestinal microbial metabolite.
[0019] Intestinal microbial metabolites have been implicated as exacerbating factors in various diseases and conditions. In other words, one or more intestinal microbial metabolites may aggravate or deteriorate a disease or a health condition. When a patient experiences an elevated serum level (concentration) of an intestinal microbial metabolite compared with a normal serum level of the intestinal microbial metabolite, the metabolite may correlate with increased risk, exacerbation, or manifestation of a disease.
[0020] In one or more embodiments, compositions comprising cucurbituril are provided to sequester, capture, or otherwise associate with one or more biomolecules. A biomolecule may be removed once captured by the cucurbituril. Methods herein may include removing a captured biomolecule from the body of a patient, for example.
[0021] A biomolecule may include at least one macronutrient that is consumed in the human diet including, but not limited to, a carbohydrate, a protein, a fat, and a vitamin. A macronutrient may be broken down by a metabolic process in the gastrointestinal tract of the body, as previously described. In one or more embodiments, a biomolecule is an intestinal microbial metabolite.
[0022] A macronutrient such as a protein may include amino acids such as tyrosine, phenylalanine, and tryptophan. An amino acid may be a protein-derived amino acid in the diet. Some amino acids are not able to be created by the human body, which are called essential nutrients (such as essential amino acids). Suitable examples of other macronutrients include a vitamin including, but not limited to, choline; an acid including, but not limited to, a short chain fatty acid such as acetic acid, propionic acid, and butyric acid, and a bile acid such as taurocholic acid, glycolic acid, deoxycholic acid; carnitine; dietary fiber; and combinations thereof.
[0023] One or more biomolecules such as a macronutrient may be metabolized by intestinal bacteria to produce an intestinal microbial metabolite. For example, intestinal microbial metabolites produced from tyrosine, phenylalanine, or tryptophan include, but are not limited to, indole, indolacetic acid, indoxyl sulfate, skatole, trimethylamine, p- cresol, 4-ethyl phenol, phenol, phenol derivative(s), homocysteine, 3-carboxy-4-methyl-5- propyl-2-furanopropionic acid, urofuranic acid(s), hippuric acid, p-hydroxyhippuric acid, and a combination thereof.
[0024] Generally, when a biomolecule is broken down to a metabolite, the metabolite may be further processed by oxidation, hydrolysis, reduction, glutathione conjugation, sulfation, acetylation, glucuronidation, another known metabolic process, and a combination thereof. Thus, an intestinal microbial metabolite may be further metabolized in the liver to produce another compound. The compound that has been further metabolized may still be called an intestinal microbial metabolite. For example, intestinal microbial metabolites that have been further metabolized may include, but are not limited to, indoxyl sulfate, hippuric acid, p-cresyl sulfate, p-cresol glucuronide, 4-ethylphenol sulfate (4EPS), trimethylamine-N trimethylamine-N-oxide (TMAO), and other suitable downstream metabolic products.
[0025] As a non-limiting example of how an elevated serum level of a metabolite is linked to health conditions, when an elevated TMAO level is present in the serum of a patient, the elevated serum TMAO level may correlate with cardiovascular disease. Likewise, an elevated serum 4EPS level may correlate with psychological conditions, such as autism spectrum disorder (ASD). In addition, an elevated serum indoxyl sulfate and/or p-cresyl sulfate level may correlate with kidney disease, such as chronic kidney disease. Chronic kidney disease may be prevalent in, for example, a dialysis patient.
[0026] Some conventional methods may be used to remove an intestinal microbial metabolite directly from the blood of patients with end-stage renal failure, such as dialysis. However, a protein-bound intestinal microbial metabolite, such as indoxyl sulfate and/or p-cresyl sulfate that is bound to albumin, is not removed sufficiently by dialysis to reduce the serum level of the metabolite. In some instances, intestinal microbial metabolite may be difficult to remove from the body by conventional means because of its structure, such as a protein-bound or a conjugate structure. In other
instances, free intestinal microbial metabolites (not protein-bound or conjugated) may also be difficult to remove from the body by conventional means.
[0027] Regarding intestinal microbial metabolites (whether protein-bound or free), factors that affect dialysis efficiency include size (molecular weight), solubility in water (hydrophilic/hydrophobic), protein binding rate (if any), and volume of distribution. In general, intestinal microbial metabolites that have low solubility in water (that are hydrophobic) are more likely to bind to proteins including, but not limited to, albumin. Conversely, intestinal microbial metabolites that have high solubility in water (that are hydrophilic) are less likely to bind to proteins including, but not limited to, albumin. The molecular weight of molecules that may be removed by dialysis are up to a size of 10,000 (104) grams per mole (g/mol) molecular weight. However, dialysis used alone for the removal of molecules with a molecular weight greater than 1 ,000 g/mol may not be as efficient as other techniques. Hemodiafiltration and hemofiltration techniques may remove molecules with a size greater than 10,000 g/mol.
[0028] For example, indoxyl sulfate has a molecular weight of about 213 g/mol and p- cresyl sulfate has a molecular weight of about 210 g/mol (in sodium salt form, or about 188 g/mol as p-cresol sulfate); intestinal microbial metabolites such as these are easily removed by dialysis if not bound to proteins. However, the molecular weight of albumin that is about 66,500 (6.65 x 104) g/mol (or 66.5 kilodalton) shows that protein-bound intestinal microbial metabolites may be difficult to remove by dialysis alone.
[0029] Thus, one or more embodiments of the present disclosure relates to removal of an intestinal microbial metabolite (or a further downstream metabolite) using a macrocyclic compound such as cucurbituril. Compositions and methods according to one or more embodiments herein may have fewer side effects and/or greater efficacy compared to conventional compositions and methods to remove a metabolite. Here, greater efficacy relates to removing an intestinal microbial metabolite sufficiently to reduce a serum level of the metabolite (whether protein-bound or free).
[0030] Conventional compositions and methods to remove a metabolite may include activated carbon, macrocycles (macrocyclic hosts), and uses thereof. For example, activated carbon may be used as an oral adsorbent and blood purification device, but it
does not allow specific control of the size of the substance that is to be adsorbed. Conventional compositions also adsorb many components that arc useful to the body. Among macrocycles, cyclodextrins may be used. However, cyclodextrins are reported to have low selectivity and low affinity due to their low binding constant (such as binding constant, Ka, of <104 M 1 (1/M)) (as reported in Rekharsky, M. V., and Inoue, Y. (1998), Complexation thermodynamics of cyclodextrins. Chem. Rev. 98, 1875-1917. doi: 10.1021/cr970015o).
[0031] Due to the low binding constant, excess concentration of cyclodextrin (and other macrocycles) may be needed to form host-guest complexes with, for example, intestinal microbial metabolites. Furthermore, cyclodextrins and other conventional macrocycles may be nephrotoxic when administered in an unmetabolized form.
[0032] Relating to host-guest complexes of cucurbituril and an intestinal microbial metabolite, the binding constant (Ka) of cucurbituril is several orders of magnitude greater than those of cyclodcxtrins in aqueous medium (as reported by: Cao, L., Sckutor, M., Zavalij, P. Y., Mlinaric-Majerski, K., Glaser, R., and Isaacs, L. (2014), Cucurbit[7]uril*guest pair with an attomolar dissociation constant; Angew. Chem. Int. Ed. 53, 988-993, doi: 10.1002/anie.201309635; Assaf, K. I., and Nau, W. M. (2015), Cucurbiturils: from synthesis to high-affinity binding and catalysis, Chem. Soc. Rev. 44, 394-418, doi: 10.1039/C4CS00273C; Barrow, S. J., Kasera, S., Rowland, M. J., del Barrio, J., and Scherman, O. A. (2015). Cucurbituril-based molecular recognition, Chem. Rev. 115, 12320-12406, doi: 10.1021/acs.chemrev.5b00341; and Shetty, D„ Khedkar, J. K., Park, K.M., and Kim, K. (2015), Can we beat the biotin-avidin pair? cucurbit[7]uril- based ultrahigh affinity host-guest complexes and their applications, Chem. Soc. Rev. 44, 8747-8761, doi: 10.1039/C5CS00631G.)
[0033] Compared to conventional compositions and methods, cucurbiturils may be nontoxic and biocompatible (as reported by: Montes-Navajas, P., Gonzalez-Bejar, M., Scaiano, J. C., and Garcia, H. (2009), Cucurbituril complexes cross the cell membrane, Photochem. Photobiol. Sci. 8, 1743-1747, doi: 10.1039/b9pp00041k; Hettiarachchi, G., Nguyen, D., Wu, J., Lucas, D., Ma, D., Isaacs, L., et al. (2010), Toxicology and drug delivery by cucurbit[n]uril type molecular containers, PLoS ONE 5:el0514, doi:
10.1371 /journal .pone.0010514; Uzunova, V. D., Cullinane, C., Brix, K., Nau,W.M., and Day, A. I. (2010), Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study. Org. Biomol. Chem. 8, 2037-2042, doi: 10.1039/b925555a; Zhang, X., Xu, X., Li, S., Wang, L.-H., Zhang, J., and Wang, R. (2018b), A systematic evaluation of the biocompatibility of cucurbit[7]uril in mice, Sci. Rep. 8:8819, doi: 10.1038/s41598- 018-27206-6; and Das D, Assaf KI and Nau WM (2019), Applications of Cucurbiturils in Medicinal Chemistry and Chemical Biology, Front. Chem. 7:619, doi: 10.3389/fchem.2019.00619.)
[0034] Cucurbituril is described as follows. As shown in FIG. 1A, cucurbituril is a macrocyclic molecule made of glycoluril (=C4H2N40I=) units linked by methylene (-CH2-) bridges. Cucurbituril may be a condensation product (polymerization) of glycoluril monomers and formaldehyde.
[0035] The name cucurbituril is derived from the cyclic molecule’s resemblance with a pumpkin of the family Cucurbitaceae . When viewed thrcc-dimcnsionally, cucurbituril has a pumpkin-like shape with an exterior band and an interior cavity. Cucurbituril has no bottom and no top. Thus, cucurbituril has an interior cavity that is accessible from the top and the bottom. The oxygen atoms in cucurbituril are located along the edges of the exterior band and are tilted inwards, forming a partly enclosed interior cavity. The exterior of cucurbituril is made up of a band of glycoluril molecules that are linked by methylene bridges.
[0036] The interior cavity of cucurbituril may capture a molecule within the interior cavity. When a molecule or a portion of a molecule is in the interior cavity, the molecule or portion thereof may be called a “guest” where the cucurbituril is the “host.” The cucurbituril molecule may function as a macrocyclic host in host-guest chemistry and supramolecular chemistry. One of ordinary skill in the art would appreciate the interaction between a host and a guest in host-guest and supramolecular chemistry to the extent that such chemical concepts would apply to cucurbituril chemically associating with and/or capturing a molecule. An inclusion complex (also known as an inclusion compound) is formed from a cucurbituril and a molecule that is captured in the cucurbituril.
[0037] In one or more embodiments, the interior cavity of cucurbituril is hydrophobic. Because the interior cavity of cucurbituril may be hydrophobic, the guest molecule may easily be incorporated into the interior cavity when the guest molecule is also hydrophobic. In one or more embodiments, a guest molecule is an intestinal microbial metabolite.
[0038] In one or more embodiments, the interior cavity of cucurbituril is lipophilic. Because the interior cavity of cucurbituril may be lipophilic, the guest molecule may easily be incorporated into the interior cavity when the guest molecule is also lipophilic. Thus, a guest molecule that is hydrophobic, lipophilic, or both hydrophobic and lipophilic may be water insoluble.
[0039] The number of glycoluril monomers in cucurbituril is represented by the letter n in FIG. 1A. In one or more embodiments, n is from 5 to 20 glycoluril monomers. A suitable cucurbituril molecule herein may have glycoluril monomers in an amount of, for example, n = 5, 6, 7, 8, 10, 13, 14, 15. As a non-limiting example, FIG. IB shows cucurbituril having 5 glycoluril monomers.
[0040] A composition comprising cucurbituril according to one or more embodiments may include cucurbituril molecules having different n number of glycoluril monomers. Sometimes, cucurbituril is described as cucurbit[n]uril (or CB[n] or CBn), where n is the number of glycoluril monomers.
[0041] When n = 5, 6, or 7 (glycoluril monomers), the interior cavity in cucurbituril is from about 4.4 angstroms (A) to about 7.3 A in diameter. When n = 8, 9, 10, 11, or 12, the interior cavity in cucurbituril is from about 8.8 A to about 15.0 A in diameter at its widest point. When n = 13, 14, or 15, the interior cavity in cucurbituril is from about 16.4 A to about 20 A in diameter at its widest point. When n = 16, 17, 18, 19, or 20, the interior cavity in cucurbituril is from about 21 A to about 28 A in diameter at its widest point.
[0042] The cucurbituril may have an interior cavity that is suitably sized for a guest molecule or a portion of a guest molecule. Meaning, the formation of the inclusion complex of cucurbituril and the guest molecule depends on the size of the cucurbituril interior cavity.
[0043] The exterior dimensions of the cucurbituril are slightly larger than the interior cavity size. For example, a cucurbituril having n-6 has a height of about 9.1 angstroms (A) and an outer diameter of about 5.8 A, while having an inner diameter of about 3.9 A.
[0044] In one or more embodiments, cucurbituril may range from about 830 to about 3,320 grams per mole (g/mol) (or from about 0.83 to about 3.32 kilodalton (KDa)). In one or more embodiments, the cucurbituril may be in a range of from about 0.5 to about 5 KDa. Thus, cucurbituril may be in a range having a lower limit of any of 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, or 3.5 KDa, and an upper limit of any of 1.0, 1.5, 2.0. 2.5, 3.0, 3.5, 4.0, 4.5, 5.0 KDa, where any lower limit may be combined with any mathematically allowed upper limit. One factor that is included in the size of cucurbituril is the n number of glycoluril monomers. For example, a single glycoluril monomer with two methylene bridges has a molecular weight of about 166 g/mol. Another factor that is included in the size of the cucurbituril is whether the cucurbituril is a conjugate, derivative, or another suitable form of cucurbituril.
[0045] In one or more embodiments, the cucurbituril is resistant to acidic pH. Resistant to acidic pH means that the cucurbituril retains its function at acidic pH, which is to trap a molecule or portion thereof as a guest molecule within the interior cavity without, for example, decomposing or breaking apart. An acidic pH may be less than 7.0. such as a pH having a lower limit of any of 0.1, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 3.5, and an upper limit of any of 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, and 7.0, where any lower limit may be combined with any mathematically allowed upper limit.
[0046] Acidic pH may be representative of a gut, stomach, intestine, colon, or other gastrointestinal location. Acidic physiological pH may be from 1.0 to 4.0, such as from 1.5 to 3.5. Such areas of the body are known to include strong acids such as hydrochloric acid (HC1). Other compounds may be mixed with HC1 in an acidic mixture within the stomach or gut including, but not limited to, compounds such as a salt, an enzyme, and a combination thereof. A salt may include, but is not limited to potassium chloride, sodium chloride, and a combination thereof. These acidic mixtures may also have an acidic pH.
[0047] The cucurbituril may be in a form selected from the group consisting of a crystalline product, an amorphous powder product, a syrup, a gel, and a combination thereof. The
cucurbituril may be a commercially available product or may be produced by a conventional method.
[0048] In one or more embodiments, a composition comprising cucurbituril herein is a pharmaceutical formulation. A pharmaceutical formulation herein includes cucurbituril as an active ingredient. A pharmaceutical formulation may include more than one active ingredient. For example, depending on what disease or health condition that the pharmaceutical formulation is used to treat, there may be one or more additional active ingredient. Examples of active ingredients in addition to cucurbituril include, but are not limited to: sodium polystyrene sulfonate and/or calcium polystyrene sulfonate corresponding with hyperpotassemia, chronic kidney disease, dialysis, and a combination thereof; cholestyramine corresponding with dyslipidemia, diarrhea (such as due to inhibition of endotoxin activity), vitamin D3 overdose, and a combination thereof; one or more of sevelamer hydrochloride, lanthanum carbonate hydrate, bixaromer, ferric citrate hydrate preparations, precipitated calcium carbonate, and sucrooxy iron hydroxide corresponding to hyperpotassemia, chronic kidney disease, dialysis, and combinations thereof; and activated charcoal corresponding to chronic kidney disease and/or acute drug poisoning.
[0049] In one or more embodiments, compositions herein include different forms of cucurbituril. For example, the term “cucurbituril” herein may refer to cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, or a combination thereof.
[0050] A cucurbituril conjugate may include a chemically modified cucurbituril where one or more carbonyl carbon of cucurbituril is an attachment point for another molecule or chemical moiety. Thus, a cucurbituril conjugate may include an ester linkage, or other suitable linkage known in the ail to chemically and physically bind the cucurbituril.
[0051] In one or more embodiments, a pharmaceutical formulation herein includes an inactive ingredient. A pharmaceutical formulation herein may include one or more component that is orally administered. For example, a pharmaceutical formulation comprising cucurbituril may include glycoluril, formaldehyde, and a combination thereof.
In one or more embodiments, a pharmaceutical formulation substantially does not include formaldehyde. Formaldehyde is generally harmful to the body of living animals including humans, and the pharmaceutical formulation including less formaldehyde is preferable. The cucurbituril may be formed from a formaldehyde-free reaction subjecting to react glycoluril monomers with a methylene bridging agent instead of formaldehyde or its precursor in the presence of an acid. The methylene bridging agent can be a dialkoxymethane, preferably diethoxymethane or dipropoxymethane. Another formaldehyde-free reaction can be a reaction of a fully alkoxy methylated glycoluril with unsubstituted glycoluril in the presence of an acid.
[0052] In one or more embodiments, the pharmaceutical formulation comprising cucurbituril is in a suitable dosage form for oral administration. Oral administration is where a substance is taken through the mouth. Examples of suitable dosage forms of a pharmaceutical formulation comprising cucurbituril include, but are not limited to, a tablet, a chew (a dissolvable solid or tablet), a capsule (hard capsule, soft capsule, gel capsule, microcapsule, or chewable capsule), a liquid, a gel, a powder, a granule (such as a fine granule), a round, a pastille, an osmotic delivery system, a decoction, an elixir, an electuary, an emulsion, an effervescent, a solution, a suspension, a tincture, a syrup, a food product including, but not limited to, a drink, and a combination thereof. The dosage form may be time-release, extended-release, or sustained release.
[0053] As a non-limiting example, the cucurbituril may be released in the colon to adsorb intestinal microbial metabolites from enteric bacteria. For such a time delay (or locationspecific) release, cellulase derivatives such as cellulase acetate phthalate (CAP) and cellulose hydroxy propyl methyl phthalate may be used. Further, a dosage form that dissolves in alkaline intestinal juice (and not, for example, in acidic gastric juice) may be used as a material in a cap, capsule, film, or other suitable dosage form where the dosage form is made from enteric soluble material.
[0054] One or more embodiments of the present disclosure relate to a method of administering a composition comprising cucurbituril to a patient in need thereof. The composition comprising cucurbituril may be a pharmaceutical composition. The method
may include administering a dose of cucurbituril by oral administration or by other means to a gastrointestinal tract, such as by a feeding tube.
[0055] The method may include administering a single dose or multiple doses in an effective amount to treat a patient having an elevated serum level of an intestinal microbial metabolite. An effective amount reduces an elevated level (concentration) of the intestinal microbial metabolite to a safe or normal level of the intestinal microbial metabolite, where concentration may be measured in a patient’s serum. The effective dose and number of doses of cucurbituril may vary depending on the type of administration, the patient’s age, body weight, nature, or severity of symptoms to be treated, overall health, other health conditions, additional medicines, and other factors.
[0056] Depending on the factors previously mentioned, a maximum allowable dose for a human is up to about 1,000 milligrams per kilogram of body weight (mg/kg/body weight) per day of cucurbituril that is orally administered.
[0057] As described previously, one or more embodiments of the method include treating a patient having an elevated scrum level of an intestinal microbial metabolite. For example, indoxyl sulfate (produced from indole in intestine) has a normal concentration of 0.53 milligrams per liter (mg/L) with a standard deviation of about 0.29 mg/L and a standard deviation of 0.29 (SD: 0.29), a mean uremic concentration of about 23.1 mg/L (SD: 13.0), and a greatest uremic concentration of about 44.5 mg/L (SD: 15.3). P-cresyl sulfate (produced from phenol in intestine) has a normal concentration of about 1.9 mg/L (SD: 1.3), a mean uremic concentration of about 20.9 mg/L (SD: 12.2), a greatest uremic concentration of about 41 mg/L (SD: 13.3).
[0058] In general, it is assumed that blood concentrations are normally distributed, and the mean value ± 2 SD is the normal value (the range in which about 95% of people are distributed). Therefore, when looking to indoxyl sulfate, about 0 to about 1.11 (0.53+0.29 x 2) mg/L is the normal value, and if this value is exceeded, this is considered an elevated serum level of the intestinal microbial metabolite (indoxyl sulfate). Similar reasoning applies to p-cresyl sulfate and other intestinal microbial metabolites.
[0059] An effective amount of cucurbituril is administered to the patient when the dose concentration is sufficient to lower an elevated serum level of an intestinal microbial metabolite to a normal serum level of the same metabolite.
[0060] The method may include allowing the cucurbituril (or derivative, etc.) to associate with the intestinal microbial metabolite, thereby capturing the intestinal microbial metabolite with the cucurbituril. Without wanting to be bound by theory, an inclusion complex may be formed by inclusion of the intestinal microbial metabolite in the cucurbituril (as a host-guest complex). As a result, a concentration (level) of an intestinal microbial metabolite in the gastrointestinal tract and serum are thought to decrease to a normal or a healthy level as compared to an elevated level, which may suppress the progression of various diseases and human health conditions.
[0061 ] In one or more embodiments, the method includes removing the intestinal microbial metabolite from the patient. Removing the intestinal microbial metabolite may include removing an inclusion complex (metabolite with cucurbituril), unused cucurbituril that may not be part of an inclusion complex, as well as free intestinal microbial metabolite.
[0062] The patient to be treated may be suffering from a disease, a disorder, or have a condition that is exacerbated by the elevated serum level of the intestinal microbial metabolite. Thus, the patient’s condition may include an elevated serum level of an intestinal microbial metabolite. For example, the condition may be selected from the group consisting of a cardiovascular disease, a cerebrovascular disease, a kidney disease, a psychiatric disorder, a gastrointestinal disorder, and other metabolic diseases and disorders, and a combination thereof.
[0063] The cardiovascular disease and/or the cerebrovascular disease is selected from the group consisting of coronary heart disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism, stroke, cerebral infarction, and a combination thereof.
[0064] An example intestinal microbial metabolite that exacerbates a cardiovascular disease and/or cerebrovascular disease includes trimethylamine N-oxide. Phosphatidylcholine in food is metabolized to trimethylamine N (TMA) by intestinal
bacteria. Trimethylamine N (TMA) is further metabolized to trimethylamine N-oxide (TMAO) by the enzyme flavin-containing monooxygenase 3 (FMA3) in the liver. Trimethylamine N-oxide (TMAO) induces the development of atherosclerosis and cardiovascular disease by, among other things, inducing macrophages to form (as reported in Koeth RA, et al.'. Intestinal microbiota metabolism of L-camitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19 : 576 to 585, 2013; and Tang WH, etal:. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368 : 1575 to 1584, 2013.)
[0065] The kidney disease is selected from the group consisting of chronic kidney disease, IgA nephropathy, and a combination thereof.
[0066] An example intestinal microbial metabolite that exacerbates a kidney disease includes indoxyl sulfate, p-cresyl sulfate, and combinations thereof. Indoxyl sulfate induces renal tubular cell injury and cell death through production of oxidative stress, among other things. Further, indoxyl sulfate stimulates renal fibrosis through TGF-bcta overexpression and activates mesangial cell proliferation. P-cresyl sulfate also causes renal tubular cell damage by inducing oxidative stress, among other things.
[0067] The psychiatric disorder is selected from the group consisting of an autism spectrum disorder, an anxiety disorder, and a combination thereof.
[0068] An example intestinal microbial metabolite that exacerbates a psychiatric disorder includes 4-ethylphenyl sulfate (4EPS). 4-Ethylphenyl sulfate (4EPS) is produced when tyrosine is metabolized by intestinal bacteria to 4-ethylphenol, which is then sulfate conjugated in liver. 4-Ethylphenol (4EP) and 4-ethylphenyl sulfate (4EPS) prevent oligodendrocyte maturation, inhibit neuronal myelin formation, and decrease connectivity in the brain, among other things. Such changes may be strong in anxiety disorders.
[0069] The gastrointestinal disorder is selected from the group consisting of irritable bowel disease, irritable bowel syndrome, intestinal permeability, colon cancer, gastrointestinal cancer, and a combination thereof.
[0070] An example intestinal microbial metabolite that exacerbates a gastrointestinal disorder includes skatole (produced from dietary tryptophan, metabolized by intestinal
microbes) and tryptamine. Skatole plays a role in the disturbance of intestinal homeostasis and in the development of intestinal bowel disease via inhibition of CYP11A1 expression and glucocorticoid production, among other things. Tryptamine is a ligand for trace amine- associated receptors and potentiates the inhibitory effect of serotonin that is involved in intestinal bowel disease, among other things.
[0071] Another example of an intestinal microbial metabolite that exacerbates a gastrointestinal disorder includes a short chain fatty acid (SCFA). Short chain fatty acids (SCFAs) include, but are not limited to, propionic acid, butyric acid, valeric acid, and combinations thereof. Short chain fatty acids (SCFAs) are produced in various parts of the intestinal tract. Among short chain fatty acids (SCFA), concentrations of acetic acid, propionic acid, and total organic acids in the feces of irritable bowel syndrome patients are greater than those of patients without irritable bowel syndrome. Excessive production of acetic acid and propionic acid in the feces of irritable bowel syndrome patients leads to decreased expression of adhesion factors and mucus production followed by increased mucosal permeability, among other things. These changes may lead to or contribute to irritable bowel syndrome.
[0072] Other conditions include, but are not limited to dementia, obesity, diabetes, dyslipidemia, malignancies, allergies, and chronic inflammatory diseases. Examples of an intestinal microbial metabolite that exacerbates dementia include, but are not limited to ammonia, p-cresol, isovaleric acid, indole, butyric acid, phenol, skatole. Examples of intestinal microbial metabolites that exacerbate diabetes, autoimmune disease(s), and infections are short chain fatty acids. Other intestinal microbial metabolites that may contribute to diabetes include trimethylamine and trimethylamine oxide. Other conditions may include liver cancer, exacerbated by an intestinal microbial metabolite such as secondary bile acids.
[0073] In one or more embodiments, a material having a composition comprising cucurbituril is biocompatible or blood-compatible, and an article at least partially formed from the material may be used in biological and medical arts. The article may include from about 0.1 to about 50 weight % of macrocyclic molecule (cucurbituril). “Biocompatible” means an ability to act and perform without impairing basic immunological functions of
the body or causing injurious, negative physiological, or toxic reactions. “Blood- compatiblc” means a feature suitable for direct contact with blood without causing an injurious, negative physiological, allergic, or toxic reaction. For example, ISO 10993-4 is a standardized method to test for blood compatibility. Under this standard, thrombogenicity, blood coagulation, platelets, hematologic items, and complement activation systems are evaluated. Saline extracts are used for hemolytic testing, immunologic testing (through complement activation), and devices in direct contact with blood. Hemolysis studies such as thrombogenicity testing should be performed using direct and indirect methods; thrombogenicity should be evaluated as part of safety studies performed in relevant animal models. As an alternative, a 4-hour canine venous heparinization model can be used to evaluate thrombogenicity.
[0074] A product to be used in biological and medical arts may be formed from the article. An example of the product is a dialysis membrane. In one or more embodiments, a method is provided that includes removing an intestinal microbial metabolite from the body of a dialysis patient using the dialysis membrane. The dialysis membrane may adsorb an intestinal microbial metabolite that may be free or bound to a protein. The intestinal microbial metabolite may be adsorbed during a dialysis process.
[0075] The article according to one or more embodiments herein further comprises a solid carrier component. The solid carrier component may be a constituent of the composition of the material comprising cucurbituril and may be another component of the article than a component made of the material comprising cucurbituril. The weight ratio between the macrocyclic molecule (cucurbituril) and the solid carrier component may be from about 1:1000 to about 1:1.
[0076] The dialysis membrane according to one or more embodiments herein may include a conventional dialysis membrane as the solid carrier component. By combination of cucurbituril with the conventional dialysis membrane, intestinal microbial metabolites may be removed by size as well as adsorption. For example, a coating of cucurbituril on a surface of the conventional dialysis membrane (that interacts with the blood) allows adsorption of intestinal microbial metabolites and the conventional dialysis membrane
allows removal of components by size. Thus, cucurbituril may be used to enhance adsorption capacity of the dialysis membrane.
[0077] The solid carrier component may comprise a polymer or other suitable solid carrier.
Suitable examples of the polymer for the solid carrier component include, but are not limited to, polyvinylchloride (PVC), polysulfone (PS), polyether sulfone (PES), polyphenylsulfone (PPSU), polyether ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide including, but not limited to, nylon, polystyrene, polyacrylate, polycarbonate, polymer containing acrylonitrile including, but not limited to, sodium acrylonitrile metarylsulfonate copolymer (AN69) (a copolymer of acrylonitrile and sodium methallyl sulfonate), polymer containing methylallylsulfonate salt, cellulose triacetate (CTA), a copolymer thereof, and a combination thereof. An example of the other suitable solid carrier is an activated charcoal (activated carbon).
[0078] One of ordinary skill in the art would appreciate that one or more additional component may be included in the article. Thus, one or more additional components may be included in the article.
[0079] The solid carrier component may be from about 0.1 to about 50 weight % of the total article.
[0080] The cucurbituril may be affixed to the solid carrier component. For example, the cucurbituril may be physically or chemically mixed, bound, and/or associated with the solid carrier component. When the solid carrier component is a polymer, the cucurbituril and the polymer may be cross-linked or otherwise attached to form a polymer including cucurbituril.
[0081] In one or more embodiments, the article has a form that may include but is not limited to a sheet, a membrane, a hollow fiber, a porous material, a particle, a foam, a textile, a granule, a non-woven, a gel, and a combination thereof.
[0082] The article may have a surface that includes cucurbituril. The cucurbituril may be exposed at the surface of the article. That is, the cucurbituril in the article may host small molecule guests to form an inclusion complex with an intestinal microbial metabolite and cucurbituril at the surface. The surface of the article may be smooth, porous, semiporous, or a combination thereof.
[0083] The article may include one or more layer that cucurbituril may be embedded in or may be exposed at the surface of the one or more layer, to an extent that a small molecule such as an intestinal microbial metabolite is accessible to the cucurbituril of each layer.
[0084] The article according to one or more embodiments may be formed by a method comprising one of coating, mixing, layering, and a combination thereof.
[0085] The article according to one or more embodiments may be formed by applying a coating comprising cucurbituril on a surface of a substrate comprising the solid carrier component. The coating may cover a part or whole of the substrate. Traditional coating techniques that are known in the art may be used.
[0086] The article according to one or more embodiments may be formed of a mixture of cucurbituril and the solid carrier component. Traditional mixing techniques that are known in the art may be used.
[0087] The article according to one or more embodiments may be formed by layering a plurality of layers. The composition formed of each of the layers may be same or different. Thus, traditional layering techniques that are known in the art may be used. Layering techniques include but are not limited to a layer-by-layer application.
[0088] In one or more embodiments, a product is provided that includes an article according to one or more embodiments.
[0089] The product may be a blood-compatible adsorbent. In one or more embodiments, the blood-compatible adsorbent may be a porous membrane such as a dialysis membrane comprising the article according to one or more embodiments. The cucurbituril contained in the article may be exposed on at least one surface of the dialysis membrane so that the cucurbituril is able to host a toxic substance in a fluid.
[0090] The product may be made from, in whole or in part, the article according to one or more embodiments. The article may also be on a portion of or the entirety of the product. For example, when the product is a catheter, the article may be provided on part of the catheter or the entire body of the catheter. As well, the catheter may be made from the article. Thus, the product may be tailored for an application depending on where the cucurbituril and adsorption effects are needed.
[0091] One or more embodiments of the present disclosure relate to a dialysis apparatus comprising an article herein. Thus, a dialysis apparatus may include a product comprising an article having cucurbituril and a solid carrier component.
[0092] One or more embodiments of a composition comprising cucurbituril and a method of use herein may be associated with an extracorporeal treatment. The dialysis apparatus may be a hemodialysis apparatus. This type of dialysis is sometimes called hemodialysis and removes extracorporeal waste and frees water from the blood, for example, when kidneys are in a state of failure in a patient. Other extracorporeal treatments include peritoneal dialysis, and adsorption with sorbents, such as charcoal or another adsorbent, and filtration that are suitable for use with one or more embodiments herein.
[0093] In a healthy person, an intestinal microbial metabolite in serum may be excreted via the kidneys with urine or by other biological mechanisms. However, in patients with a health condition, an intestinal microbial metabolite may remain in the patient’s blood, to be removed by dialysis. The intestinal microbial metabolite may be difficult to remove when bound to a protein, such as albumin. In some instances, one or more additional components may be added to the blood of a patient to separate a protein (such as albumin) from a metabolite during dialysis. However, conventional methods of separation may be inefficient, may increase general dosage of medications for a patient, and may decrease the patient’ s quality of life compared to one or more embodiments of a dialyzer herein and methods of use.
[0094] In one or more embodiments, a protein-bound intestinal microbial metabolite may be efficiently removed with articles and products described herein without administering medicine, or an additional medicine that disrupts the protein-metabolite complex (inclusion complex), to a patient in need of dialysis.
[0095] As previously mentioned, an intestinal microbial metabolite present in serum may be in a protein-bound form. This is because the intestinal microbial metabolite alone may have poor or low water solubility (is hydrophobic). When the intestinal microbial metabolite is bound to a protein, then transport of the metabolite may occur in aqueous medium, serum, blood, and other biological fluids via the carrier protein. The protein that binds the intestinal microbial metabolite includes but is not limited to albumin.
[0096] An intestinal microbial metabolite that is bound to a protein has a larger molecular mass than the metabolite alone that is not protein-bound. A low molecular mass intestinal microbial metabolite may be less than 50 g/mol. An average molecular mass may be between 50 and 5,000 g/mol. A large molecular mass may be greater than 5,000 g/mol. A protein-bound intestinal microbial metabolite may fall within the large molecular mass range.
[0097] One or more embodiments of the present disclosure includes removing a proteinbound intestinal microbial metabolite from serum. Thus, the protein-bound intestinal microbial metabolite may be effectively removed even at sizes that do not readily diffuse across a dialysis membrane, such as a (large) molar mass from about 65,000 to 70,000, which is about the size of albumin present in serum and a metabolite bound thereto.
[0098] FIG. 2 shows a cucurbituril-containing dialyzer 200 with a cucurbituril-containing dialysis bag 202, according to one or more embodiments. The cucurbituril-containing dialyzer is depicted as a simplified version for clarity. A person of ordinary skill in the art would appreciate variations of dialyzers that are known in the art.
[0099] As shown in FIG. 2, blood is introduced into a blood inlet 210 where it passes to the blood compartment 206. From the blood compartment, the blood passes to the blood outlet 212, through which the blood exits the cucurbituril-containing dialyzer 200. Likewise, dialysate is introduced into a dialysate inlet 214 where it passes to the dialysate compartment 208. From the dialysate compartment, the dialysate passes to the dialysate outlet 216, through which the dialysate exits the cucurbituril-containing dialyzer 200.
[00100] In the cucurbituril-containing dialyzer 200, the dialysis membrane includes or is made from an article (containing cucurbituril) according to one or more embodiments and
is called a cucurbituril-containing dialysis membrane 204. The cucurbituril-containing dialysis membrane separates the blood compartment 206 from the dialysate compartment 208. The cucurbituril-containing dialysis membrane 204 allows free intestinal microbial metabolite 220 (unbound to a protein 222) to pass over the cucurbituril-containing dialysis membrane 204. Once the free intestinal microbial metabolite 220 crosses the dialysis membrane, it may pass from the dialysate compartment 208 through the dialysate outlet 216 and exit the dialyzer 200 for further processing and/or removing steps. The dialysate may be recycled and reintroduced, or removed and fresh dialysate may be introduced into the dialysate inlet 214.
[00101] However, as shown in FIG. 2 (and FIG. 3) a protein-bound intestinal microbial metabolite 224 may not pass through a dialysis membrane because the holes in the membrane are too small for the protein-bound intestinal microbial metabolite to pass through.
[00102] In some instances, the cucurbituril-containing dialysis membrane 204 may also trap an intestinal microbial metabolite that is protein-bound. In other instances, the cucurbituril-containing dialysis membrane 204 may trap a free intestinal microbial metabolite. When the cucurbituril in the cucurbituril-containing dialysis membrane 204 associates with a protein-bound intestinal microbial metabolite 224, the binding affinity of the metabolite for the protein decreases from its protein-bound state to an extent that the metabolite may separate from the protein. As the metabolite separates or frees from the protein, cucurbituril in the cucurbituril-containing dialysis membrane may bind with the free intestinal microbial metabolite to form an inclusion complex 207. In one or more embodiments, the cucurbituril in the cucurbituril-containing dialysis membrane may retain a protein-bound intestinal microbial metabolite without separation of the metabolite from the protein. Meaning, an inclusion complex may be formed between the cucurbituril in the membrane and the protein-bound metabolite. Nonetheless, even in this case the intestinal microbial metabolite may be efficiently captured for later removal in the blood compartment of a dialyzer according to one or more embodiments.
[00103] Removing the free metabolite may occur via the dialysate outlet during filtration.
Removing the inclusion complex of the intestinal microbial metabolite (protein-bound or
free) and the cucurbituril may occur by removing the dialyzer from the apparatus and cither replacing with a new dialyzer or flushing the dialyzer with an appropriate fluid to remove the intestinal microbial metabolite that may be bound to the cucurbituril in an inclusion complex.
[00104] The cucurbituril-containing dialysis membrane may be integrated into any suitable portion of the dialysis apparatus that contacts blood or serum, including, but not limited to, a bag, a blood cap, a fiber membrane, and a combination thereof. As shown in FIG. 2, the cucurbituril-containing dialysis membrane may be included in a dialyzer. Alternatively, or in addition, the cucurbituril-containing dialysis membrane may be a separate bag or a cartridge that is upstream of a dialyzer.
[00105] A method of treating a patient having an elevated serum level of a microbial metabolite may include the following steps. First, the method may include identifying an elevated serum level of an intestinal microbial metabolite in a patient. Second, the method may include passing blood from the patient to a product containing an article. Third, the method may include allowing the intestinal microbial metabolite to contact the cucurbituril, thereby capturing the intestinal microbial metabolite with the cucurbituril in an inclusion complex. Fourth, the method may include removing the captured microbial metabolite, thereby forming an inclusion complex and an intestinal microbial metabolite- depleted blood. The method may include passing the metabolite-depleted blood back to the patient.
[00106] In one or more embodiments, the article is effective when the metabolite to be removed is bound to a protein as carrier protein. The protein may be a serum protein including, but not limited to albumin (such as human albumin), oci-acid glycoprotein, alpha 1-acid glycoprotein (AGP), a lipoprotein, an immunoglobulin, and mixtures thereof. In one or more embodiments, the article is effective when the metabolite to be removed is free, or is not protein bound.
[00107] An amount of intestinal microbial metabolite in serum that may be removed based on a safe dose (or effective amount of cucurbituril) may vary based on the individual’s health condition. For example, in the case of indoxyl sulfate, the average concentration in healthy subjects is less than 10 micromolar (pM), but in patients with end-stage chronic
renal failure, the average concentration is about 250 pM and may reach up to about 550 pM (117.27 mg/L for a molecular weight of 213.21 g/mol). A 60 kilogram (kg) person has a blood volume of approximately 4.6 liters (L), which means that about 539 milligrams (mg) of cucurbituril may be present in the blood according to the aforementioned concentration(s). During removal of intestinal microbial metabolite, amino acids and vitamins may also be adsorbed. Such amino acids and vitamins may also be replenished in the patient.
[00108] In one or more embodiments, a composition called a “molecular composite” is provided that comprises cucurbituril and one or more macrocyclic compound in addition to the cucurbituril. The molecular composite may be biocompatible. The molecular composite is an adsorbent for the removal of a protein-bound intestinal microbial metabolite. Methods herein may be used to support an extracorporeal treatment including dialysis (or hemodialysis) with a dialyzer, filtration with a hemofiltration apparatus, and other techniques that are known to one of ordinary skill in the art.
[00109] The one or more macrocyclic compound in addition to cucurbituril may include a cyclic oligosaccharide such as a pillararene, a calixarene, a derivative thereof, and a combination thereof.
[00110] As previously mentioned, an intestinal microbial metabolite may bind to a protein in human blood and serum. The metabolite may also bind to a protein in other biological fluids such as interstitial fluid, peritoneal fluid, third space fluid, including cerebrospinal fluid, gastrointestinal tract fluid, urinary tract fluid, gland fluid, cavity fluid, and other biological liquids. When an intestinal microbial metabolite is present at an elevated level in a patient’s serum, this metabolite may be a toxic substance. One of ordinary skill in the art would appreciate other toxic substances that may be present in serum.
[001 1 1 ] A displacer is a substance that may bind to a protein, such as a protein in human blood or serum, and displace a toxic substance such as an intestinal microbial metabolite. A displacer may be natural, such as bilirubin, and/or albumin, or it may be synthetic such as acetaminophen. A displacer may competitively bind to a protein while displacing a metabolite that was previously bound to the protein.
[00112] In one or more embodiments, the cucurbituril may be mixed in a molecular composite that is added to pre-dialysis blood. Macrocyclic components in the molecular composite may form an inclusion complex with the toxic substance such as an intestinal microbial metabolite. The inclusion complex may be removed by dialysis, filtration, or another suitable extracorporeal treatment of removal including, but not limited to, extracorporeal renal replacement therapy.
[00113] FIG. 3 shows a molecular composite dialyzer 300 with a molecular composite dialysis bag 302, according to one or more embodiments herein. The molecular composite dialyzer 300 includes a molecular composite distributor 303 that is coupled to the blood compartment 206.
[00114] In FIG. 3, the molecular composite distributor 303 is affixed to the blood compartment. However, a molecular composite distributor may be accessible to the blood compartment by a conduit such as a tube or a pipe. A molecular composite distributor may also be a means of introducing a molecular composite into the blood compartment such as an injection. The molecular composite may also be a combination of the above-mentioned molecular composites. In FIG. 3, the dialysis membrane 304 may be a conventional dialysis membrane or it may be a cucurbituril-containing dialysis membrane (as shown in FIG. 2).
[00115] As shown in FIG. 3, blood is introduced into a blood inlet 210 where it passes to the blood compartment 206. From the blood compartment, the blood passes to the blood outlet 212through which the blood exits the molecular composite dialyzer 300. Likewise, dialysate is introduced into a dialysate inlet 214 where it passes to the dialysate compartment 208. From the dialysate compartment, the dialysate passes to the dialysate outlet 216 through which the dialysate exits the molecular composite dialyzer 300.
[00116] As the molecular composite including cucurbituril passes from the molecular composite distributor 303 to the blood compartment 206, the cucurbituril 305 in the molecular composite may intermingle with a protein-bound intestinal microbial metabolite 224 or a free intestinal microbial metabolite (not protein-bound). As the molecular composite associates with the toxic substance or intestinal microbial metabolite, the protein may dissociate from the captured toxic substance upon binding
and formation of an inclusion complex. As previously described, an inclusion complex 306 may be formed between the cucurbituril (and/or molecular composite) and the toxic substance or the intestinal microbial metabolite. In one or more embodiments, the inclusion complex 306 is much smaller than the protein-bound intestinal microbial metabolite 224 so that it can pass through the pore of the dialysis membrane 304. The inclusion complex formed of at least one of cucurbituril formed from 5 to 10 glycoluril monomers is especially preferable with its size. The inclusion complex 306 formed in the blood compailment 206 may pass through the dialysis membrane 304 to the dialysate compartment 208 following the concentration gradient.
[00117] In one or more embodiments, the method includes removing the captured toxic substances from the blood of a patient. A free intestinal microbial metabolite may pass through the dialysis membrane 304 to the dialysate compartment 208. Inclusion complexes including cucurbituril and a toxic substance such as an intestinal microbial metabolite may pass through the dialysis membrane 304 (in the case of, for example, hemodiafiltration where this process removes inclusion complexes with proteins such as albumin). Thus, the intestinal microbial metabolite may pass from the molecular composite dialyzer 300 via the dialysate outlet 216 and exit the system. The method may include flushing the dialysate compartment with further dialysate, thereby removing the toxic substances from the dialyzer.
[00118] Benefits of the method of introducing the molecular composite in pre-dialysis blood include an increased efficiency of protein-bound metabolite removal compared to without the molecular composite. Toxicity is reduced (and safety is improved) compared to when using bilirubin, cyclodextrin or other conventional macrocycle, or another compound that displaces intestinal microbial metabolites bound to albumin. Cost is also reduced; for example, conventional displacement methods such as administering albumin is expensive and impractical on a daily basis, whereas cucurbituril is lower cost. Cucurbituril is also more efficient in binding intestinal microbial metabolites compared to cyclodextrin (and other conventional macrocycles).
[00119] Unless defined otherwise, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art to which these systems, apparatuses, methods, processes, and compositions belong.
[00120] The singular forms “a,” “an,” and “the” include plural referents, unless the context clearly dictates otherwise.
[00121] As used here and in the appended claims, the words “comprise,” “has,” and “include” and all grammatical variations thereof are each intended to have an open, nonlimiting meaning that does not exclude additional elements or steps.
[00122] “Optionally” means that the subsequently described event or circumstances may or may not occur. The description includes instances where the event or circumstance occurs and instances where it does not occur.
[00123] When the word “approximately” or “about” is used, this term may mean that there can be a variance in value of up to ±10%, of up to 5%, of up to 2%, of up to 1%, of up to 0.5%, of up to 0.1%, or up to 0.01%.
[00124] The term “substantially” as used refers to a majority of, or mostly, as in at least about 50%. 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.
[00125] Ranges may be expressed as from about one particular value to about another particular value, inclusive. When such a range is expressed, it is to be understood that another embodiment is from the one particular value to the other particular value, along with all particular values and combinations thereof within the range.
[00126] Although only a few example embodiments have been described in detail above, those skilled in the ail will readily appreciate that many modifications are possible in the example embodiments without materially departing from this invention. Accordingly, all such modifications are intended to be included within the scope of this disclosure as defined in the following claims.
Claims
What is claimed is:
1. A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite, comprising: an effective amount of a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof, wherein the macrocyclic molecule comprises 5 to 20 glycoluril monomers.
2. The pharmaceutical formulation of claim 1, wherein the patient has a condition that is exacerbated by an intestinal microbial metabolite; the condition selected from the group consisting of a cardiovascular disease, a cerebrovascular disease, a kidney disease, a psychiatric disorder, a gastrointestinal disorder, and a combination thereof.
3. A method of treating a patient with an elevated serum level of an intestinal microbial metabolite, comprising: administering a dose comprising the pharmaceutical formulation of claim 1.
4. The method of claim 3, wherein the dose is administered by oral administration.
5. The method of claim 3, further comprising allowing the macrocyclic molecule to associate with the intestinal microbial metabolite, thereby capturing the intestinal microbial metabolite and forming an inclusion complex.
6. The method of claim 5, further comprising removing the inclusion complex from the patient.
7. The method of claim 3, wherein the patient has a condition that is exacerbated by the intestinal microbial metabolite; the condition selected from the group consisting of a cardiovascular disease, a cerebrovascular disease, a kidney disease, a psychiatric disorder, a gastrointestinal disorder, and a combination thereof.
An article, comprising: a macrocyclic molecule selected from the group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof; and a solid carrier component selected from the group consisting of polyvinylchloride (PVC), polysulfone (PS), polyether sulfone (PES), polyphenylsulfone (PPSU), polyether ether ketone (PEEK), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), polyethylene (PE), polyurethane (PU), polyetherimide (PEI), polycarbonate (PC), polypropylene (PP), polyoxymethylene (POM), polymethyl methacrylate (PMMA), polyester polymer alloy (PEPA), polyglycolic acid (PGA), cellulose triacetate, ethylene vinyl alcohol (EVOH), ethylene vinyl acetate (EVA), polyphenol, polyamide, nylon, polystyrene, poly acrylate, polycarbonate, polymer containing acrylonitrile, sodium acrylonitrile metarylsulfonate copolymer (AN69), polymer containing methylallylsulfonate salt, cellulose triacetate (CTA), a copolymer thereof, and combinations thereof. The article of claim 8, wherein the article is selected from the group consisting of a sheet, a membrane, a hollow fiber, a porous material, a particle, a foam, a textile, a granule, a nonwoven, and combinations thereof. The article of claim 9, composed of a coating comprising the macrocyclic molecule and a substrate comprising the solid carrier component, wherein the coating covers at least a part of the substrate. The article of claim 9, formed of a mixture of the macrocyclic molecule and the solid carrier component. A product comprising the article of claim 9, wherein the product is a blood-compatible adsorbent. The product of claim 12, wherein the blood-compatible adsorbent is a dialysis membrane.
A method of treating a patient having an elevated serum level of an intestinal microbial metabolite, comprising: passing blood from the patient to an article or a product containing the article of claim 8; and allowing the intestinal microbial metabolite to contact the macrocyclic molecule, thereby capturing the intestinal microbial metabolite with the cucurbituril in an inclusion complex. The method of claim 14, further comprising removing the inclusion complex, thereby forming a metabolite-depleted blood. The method of claim 15, further comprising passing the metabolite-depleted blood back to the patient. A molecular composite, comprising: a macrocyclic molecule selected from a group consisting of a cucurbituril, a cucurbituril derivative, a cucurbituril conjugate, a pharmaceutically acceptable salt of cucurbituril, an isomer of cucurbituril, a tautomer of cucurbituril, a solvate of cucurbituril, an isotopic variation of cucurbituril, and a combination thereof; and an additional macrocyclic molecule selected from a group consisting of a cyclic oligosaccharide, a pillararene, a calixarene, a derivative thereof, and a combination thereof. A method of removing a toxic substance from a patient that has an elevated serum level of the toxic substance, comprising: introducing the molecular composite of claim 17 into blood of the patient; and allowing the molecular composite to associate with the toxic substance, thereby binding to the toxic substance and forming an inclusion complex. The method of claim 18, further comprising releasing the toxic substance from a protein, before forming the inclusion complex.
20. The method of claim 18, further comprising removing the inclusion complex from the blood of the patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263411277P | 2022-09-29 | 2022-09-29 | |
US63/411,277 | 2022-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024073056A1 true WO2024073056A1 (en) | 2024-04-04 |
Family
ID=88558479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/034135 WO2024073056A1 (en) | 2022-09-29 | 2023-09-29 | Cucurbituril compositions, products, and methods of use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024073056A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030140787A1 (en) * | 1999-05-07 | 2003-07-31 | Day Anthony Ivan | Cucurbiturils and method for binding gases and volatiles using cucurbiturils |
WO2015091842A2 (en) * | 2013-12-20 | 2015-06-25 | Fresenius Medical Care Deutschland Gmbh | Method for removing protein-bound uremic toxins by adsorption to auxiliary substances that can be subjected to dialysis |
US20180369783A1 (en) * | 2017-06-22 | 2018-12-27 | B. Braun Avitum Ag | Hemocompatible adsorber for the dialysis of protein-bound uremic toxins |
-
2023
- 2023-09-29 WO PCT/US2023/034135 patent/WO2024073056A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030140787A1 (en) * | 1999-05-07 | 2003-07-31 | Day Anthony Ivan | Cucurbiturils and method for binding gases and volatiles using cucurbiturils |
WO2015091842A2 (en) * | 2013-12-20 | 2015-06-25 | Fresenius Medical Care Deutschland Gmbh | Method for removing protein-bound uremic toxins by adsorption to auxiliary substances that can be subjected to dialysis |
US20180369783A1 (en) * | 2017-06-22 | 2018-12-27 | B. Braun Avitum Ag | Hemocompatible adsorber for the dialysis of protein-bound uremic toxins |
Non-Patent Citations (17)
Title |
---|
AKTANOVA ALINA ET AL: "Assessment of the Biocompatibility of Cucurbiturils in Blood Cells", NANOMATERIALS, vol. 11, no. 6, 21 May 2021 (2021-05-21), pages 1356, XP093112344, ISSN: 2079-4991, Retrieved from the Internet <URL:https://www.mdpi.com/2079-4991/11/6/1356/pdf> DOI: 10.3390/nano11061356 * |
ASSAF, K. I.NAU, W. M.: "Cucurbiturils: from synthesis to high-affinity binding and catalysis", CHEM. SOC. REV., vol. 44, 2015, pages 394 - 418 |
BARROW, S. J.KASERA, S.ROWLAND,M. J.DEL BARRIO, J.SCHERMAN, O. A.: "Cucurbituril-based molecular recognition", CHEM. REV., vol. 115, 2015, pages 12320 - 12406, XP055466999, DOI: 10.1021/acs.chemrev.5b00341 |
CAO, L.SCKUTOR, M.ZAVALIJ, P. Y.MLINARIC-MAJERSKI, K.GLASER, R.ISAACS, L.: "Angew. Chem.", vol. 53, 2014, article "Cucurbit[7]uril guest pair with an attomolar dissociation constant", pages: 988 - 993 |
DAS DASSAF KINAU WM: "Applications of Cucurbiturils in Medicinal Chemistry and Chemical Biology", FRONT. CHEM., vol. 7, 2019, pages 619 |
DAY, A. I.: "Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study", ORG. BIOMOL. CHEM., vol. 8, 2010, pages 2037 - 2042 |
GAO CUI ET AL: "Recent trends in therapeutic application of engineered blood purification materials for kidney disease", BIOMATERIALS RESEARCH, 4 February 2022 (2022-02-04), XP093097398, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815201/pdf/40824_2022_Article_250.pdf> [retrieved on 20231102], DOI: 10.1186/s40824-022-00250-0 * |
HETTIARACHCHI, G.NGUYEN, D.WU, J.LUCAS, D.MA, D.ISAACS, L. ET AL.: "Toxicology and drug delivery by cucurbit[n]uril type molecular containers", PLOS ONE, vol. 5, 2010, pages el0514 |
KOETH RA ET AL.: "Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis", NAT. MED., vol. 19, 2013, pages 576 - 585, XP055628343, DOI: 10.1038/nm.3145 |
LAGONA J ET AL: "THE CUCURBIT[n]URIL FAMILY", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 44, no. 31, 5 August 2005 (2005-08-05), pages 4844 - 4870, XP001232746, ISSN: 1433-7851, DOI: 10.1002/ANIE.200460675 * |
MA YUHAO ET AL: "Adsorption-based strategies for removing uremic toxins from blood", MICROPOROUS AND MESOPOROUS MATERIALS, ELSEVIER, AMSTERDAM ,NL, vol. 319, 18 March 2021 (2021-03-18), XP086576363, ISSN: 1387-1811, [retrieved on 20210318], DOI: 10.1016/J.MICROMESO.2021.111035 * |
MONTES-NAVAJAS, P.GONZALEZ-BEJAR, M.SCAIANO, J. C.GARCIA, H.: "Cucurbituril complexes cross the cell membrane", PHOTOCHEM. PHOTOBIOL. SCI., vol. 8, 2009, pages 1743 - 1747 |
REKHARSKY, M. V.INOUE, Y.: "Complexation thermodynamics of cyclodextrins", CHEM. REV., vol. 98, 1998, pages 1875 - 1917 |
SHETTY, D.KHEDKAR, J. K.PARK, K.M.KIM, K.: "Can we beat the biotin-avidin pair? cucurbit[7]uril-based ultrahigh affinity host-guest complexes and their applications", CHEM. SOC. REV., vol. 44, 2015, pages 8747 - 8761, XP055456926, DOI: 10.1039/C5CS00631G |
STEVEN J. BARROW ET AL: "Cucurbituril-Based Molecular Recognition", CHEMICAL REVIEWS, vol. 115, no. 22, 13 November 2015 (2015-11-13), US, pages 12320 - 12406, XP055466999, ISSN: 0009-2665, DOI: 10.1021/acs.chemrev.5b00341 * |
TANG WH ET AL.: "Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk", N. ENGL. J. MED., vol. 368, 2013, pages 1575 - 1584, XP055448252, DOI: 10.1056/NEJMoa1109400 |
ZHANG, X.XU, X.LI, S.WANG, L.-H.ZHANG, J.WANG, R.: "A systematic evaluation of the biocompatibility of cucurbit[7]uril in mice", SCI. REP., vol. 8, 2018, pages 8819 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matoori et al. | Recent advances in the treatment of hyperammonemia | |
JP3337216B2 (en) | Equipment for extracorporeal treatment of blood | |
US8038638B2 (en) | Plasma detoxification and volume control system and methods of use | |
JP3486190B2 (en) | Membrane and method for separating protein-binding substance from protein-containing liquid by dialysis | |
EP1765433B1 (en) | Plasma detoxification and volume control system | |
JP7048425B2 (en) | Blood-compatible adsorbent for dialysis of protein-binding uremic toxins | |
Reiter et al. | In vitro removal of therapeutic drugs with a novel adsorbent system | |
Faria et al. | Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease | |
WO2005082504A2 (en) | Plasma detoxification system and methods of use | |
CN110269867A (en) | Composition for biofluid purification | |
WO2024073056A1 (en) | Cucurbituril compositions, products, and methods of use | |
Ash et al. | Treatment of severe tricyclic antidepressant overdose with extracorporeal sorbent detoxification | |
WO2001024790A1 (en) | Agents for relieving carbonyl stress | |
Marcello et al. | Bilirubin Adsorption with DPMAS: Mechanism of Action and Efficacy of Anion Exchange Resin | |
Papadopoulou et al. | The Use of Hemoperfusion in Children: Past, Present, and Future | |
KR100752414B1 (en) | Artificial liver system of plasma separation, adsorption and filtration | |
TWI595897B (en) | Blood Purification System | |
CN104394903B (en) | The purification of biofluid | |
CN214512103U (en) | Blood purification device for treating poisoning | |
Hew et al. | Liver support systems: The low clearance of model hepatic excretory anions by charcoal hemoperfusion | |
Wang et al. | Recent advances in blood toxin removal technology | |
Watkins | Dialysis and hemoperfusion for poisoning | |
Berman | The art and science of clinical toxicology | |
Hoenich | Biocompatibility of sorbent systems | |
Vanholder et al. | Hemodialysis, Ultrafiltration, and Hemofiltration |